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Abstract 
 
 
 Melanoma manifests itself from the malignant transformation of melanocytes and 
represents the deadliest form of skin cancer, being responsible for the disproportionate 
majority of all skin cancer deaths. The 2002 discovery that 50% of all melanoma 
patients possess activating BRAF mutations ignited a significant paradigm shift in the 
way the melanoma field approached research and how patients were treated [1]. The 
era of targeted therapy had begun and with it came successful targeted BRAF inhibitor 
therapy regimens, which have accomplished improved clinical benefit (response rate, 
progression free survival, and overall survival) compared with treatment with 
chemotherapy in three phase III clinical trials [2]. Although there has been much 
success in the subgroup of patients whose melanomas harbor activating BRAF 
mutations, approximately 50% of all melanoma patients do not harbor BRAF mutations. 
This subgroup of melanoma is composed of ~15-20% of all patients with NRAS 
mutations and another ~25-30% of patients with neither BRAF nor NRAS mutations. 
Successful targeted treatment strategies are currently lacking for this subgroup of 
BRAF-wild type melanomas and therefore novel targeted therapeutic modalities are 
urgently needed.  
 The work described in this dissertation sheds light on potential approaches for 
the treatment of BRAF wild type melanoma and will be split into three separate 
strategies. The first will focus upon the treatment of melanomas without BRAF or NRAS 
	   xi 
mutations (BRAF/NRAS wild type melanoma) and will expand upon a clinical 
observation where two melanoma patients were treated with an experimental 
combination of carboplatin and paclitaxel, with the addition of the AKT inhibitor MK-
2206. We demonstrate that the inhibition of AKT significantly enhances the efficacy of 
chemotherapy in a reactive oxygen species (ROS) mediated fashion, and an induction 
of autophagy plays a cyto-protective role. The second story focuses upon the treatment 
of NRAS mutant melanomas by investigating resistance mechanisms to MEK inhibitor 
treatment. We discovered a MEKi-mediated induction of receptor tyrosine kinase (RTK) 
signaling to serve as a significant mechanism of escape for NRAS mutant melanomas 
treated chronically with the MEK inhibitor AZD6244, as well as the recently U.S. Food 
and Drug Administration (FDA) approved MEK inhibitor trametinib. Novel targeted 
therapy combinations were then added to overcome the escape from MEK inhibitor 
therapy. Co-targeting of the receptor tyrosine kinases AXL, PDGFR-β and c-MET with a 
pan-RTK inhibitor, as well as the mitogen-activated protein kinase (MAPK) pathway with 
a MEK inhibitor greatly enhanced treatment-induced apoptosis and inhibition of 
proliferation. The final strategy builds upon the observation that single agent MEK-
inhibition is largely ineffective in the treatment of NRAS mutant melanomas. A recovery 
of MAPK pathway activity in response to MEK inhibition was established to play a 
significant role in escape of NRAS mutant cells from cell cycle arrest and apoptosis. The 
combination of a MEK inhibitor with the novel ERK inhibitor VTX-11e prevents the onset 
of resistant clones and enhances cytotoxicity of the NRAS mutant melanoma cells. 
 This body of work establishes original targeted therapy combinations for the 
treatment of both NRAS mutant melanomas and BRAF/NRAS wild type melanomas. 
	   xii 
We propose future clinical investigation with these strategies in the treatment of BRAF 
wild type melanoma patients in hopes to further extend overall survival.  
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Chapter 1 
 Introduction 
Introduction to Melanoma 
This is an exciting time for the treatment of metastatic melanoma, as what was 
previously seen as an untreatable disease is now divulging its molecular weaknesses 
and oncogene addictions.  The melanoma field has become rejuvenated with recent 
discoveries revealing the genetic basis of melanoma tumors. The increase in 
therapeutic options available for patients have resulted in both enhanced clinical 
response rates and improvements in overall survival [3]. 2011 was a benchmark year 
for the treatment of melanoma with the FDA approval of two novel agents, vemurafenib 
(BRAF inhibitor) and ipilimumab (an anti-CTLA4 antibody) [4] (Figure 1). Both of these 
agents were shown to extend overall survival of melanoma patients with disseminated 
disease in randomized phase III trials. However, forgotten in the recent excitement 
these discoveries have generated is the fact that melanoma is an incredibly old disease 
with an intriguing history that has long frustrated earlier attempts at therapeutic 
intervention. To fully appreciate the advances that have been made in the past few 
decades, we must also understand what has been documented and accomplished in 
the past. In addition to providing significant advances in modalities capable of treating 
BRAF wild type melanomas, this thesis will also outline the rich history of melanoma; 
from the oldest evidence of melanoma found in the form of excavated mummies of pre-
Colombian Incas of Peru, to the observations of 18th/19th century physicians who first 
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defined melanoma as a distinct disease, up through the molecular revolution of the 20th 
century that made the discovery of key oncogenic drivers of melanoma possible. These 
insights provided the intellectual foundation the work in this manuscript as relied on to 
further the collected knowledge of melanoma.  
 
History of Melanoma 
Melanoma is in fact an archaic malady with the first documented descriptions of 
melanoma in history appearing in the ancient writings of Hippocrates of Kos (sometime 
in the fifth century B.C.) (Figure 1). The name melanoma is derived from the Greek 
words “melas”	  meaning dark and “oma”	  meaning tumor [5]. Despite having little in the 
way of archeological evidence of cancer from the past, traces of melanoma have been 
propitiously discovered from the diffuse melanotic metastases found in mummies of 
Pre-Columbian Incas of Peru [5]. Seven mummies were excavated from Chancay and 
another 2 mummies were uncovered from Chongos. With the use of radiocarbon 14 
dating, the mummies are estimated to be ~2400 years old (Figure 1) [5].  
Somewhere between 1650 and 1760, the European medical literature began 
referencing ‘fatal black tumors with metastases and black fluid in the body’. These 
descriptions were discovered in the works of Highmore (1651), Bonet (1651) and 
Henrici and Nothnagel (1757). John Hunter, a Scottish surgeon, was noted to have 
performed the first surgical removal of a melanoma in 1787, although melanoma was 
not yet defined as a distinct disease until 1804. He operated on a 35-year-old man and 
removed a recurrent melanoma from his jaw. Hunter described the tumor as a 
‘cancerous fungous excrescence’ [6].	  The tumor was later definitively diagnosed as a 
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melanoma in 1968 and, to this date, is still housed in the Hunterian Museum in London, 
UK [7]. Melanoma was not defined as a distinct disease before the 19th century, and 
often categorized along with the black carbon deposits commonly found in autopsies of 
patients lungs [8, 9]. It was not until Rene Laennec, a French physician (more famed for 
the invention of the stethoscope), coined the term melanose to describe these tumors in 
an 1804 lecture in Paris that the scientific community officially recognized melanoma as 
a disease in its own right. Of interest, Laennec was a student of Baron Dupuytren, 
whom served as surgeon to Napoleon Bonaparte and Laennec’s seminal report on 
melanoma led to a quarrel between the former mentor and student, since the Baron did 
not feel properly acknowledged for his own work by Laennec [10]. Another pupil of 
Dupuytren, Jean Cruveilhier, was the first to describe the existence of melanomas on 
the hand, vulva and foot [10]. 
Some of the first insightful reports into the initiation and progression of melanoma 
were provided by Dr. William Norris in 1820, through his descriptions of ‘fungoid 
disease’	  on his patients [11]. By documenting disease progression and logging detailed 
anatomical observations upon autopsy, Norris made a number of major revelations that 
continue to be of upmost interest to the melanoma field to date. One worth mentioning 
is an observation Norris made while making an incision through a melanoma tumor: ‘I 
found the texture to be heterogeneous; it was of a reddish and whitish brown tint 
throughout, not very unlike the internal structure of a nutmeg’ [11]. Norris also remarked 
upon the incredible tendency of melanomas to metastasize ‘On opening the abdomen I 
found numerous tubers of various sizes…it was interesting to behold the tumors 
scattered in the utmost profusion in every direction’	  [11].	  Just as remarkable, Norris was 
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also the first to comment on the heritable nature of melanoma, almost 50 years before 
Mendel presented his data on inheritance. Norris stated: ‘It is remarkable that this 
gentleman’s father died of a similar disease…. This tumor, I have remarked, originated 
in a mole…my patient and his children had many moles on various parts of their 
bodies…. These facts, together with another case that has come under my 
notice...would incline me to believe that this disease is hereditary’ [11]. In 1857, Norris 
developed some general principles for melanoma epidemiology and clinical 
management from insight he collected on another eight cases of melanoma [12]. He 
was one of the first to suggest a relationship between nevi and melanoma, as well as 
correlations between melanoma, pale complexions and exposure to environmental 
factors, including industrial pollution [12, 13].  
Once disseminated, therapeutic options for melanoma patients were severely 
limited before the era of chemotherapy, targeted agents and immunotherapy. 
Investigators from the past recognized this with a report as early as 1826 from the 
physician Thomas Fawdington stating, “as we have no positive indications to guide us 
towards the cure of melanosis, the treatment directed, in the present instance, is, of 
course, purely palliative” [13, 14].  The British surgeon Samuel Cooper published The 
First Lines of the Theory and Practice of Surgery in 1844 regarding melanoma. In 1840, 
Cooper realized that metastatic melanomas were nearly impossible to treat given the 
therapeutic options available at the time and stated, ‘the only chance for benefit 
depends upon the early removal of the disease…’, an observation that largely holds 
true to this day [13, 15]. In 1853, a Consulting Surgeon by the name of Sir James Paget 
reported on 25 cases of melanoma where he first described the transition from a radial 
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growth phase to a vertical growth phase in melanomas moving from a benign to a more 
malignant, invasive phenotype [16]. A few years later, Oliver Pemberton provided 
detailed medical logs of 60 melanoma cases from 1820-1857. His contributions 
provided some of the first clinical characteristics and sites of metastases for melanoma 
[17].                                    
 
Surgical Management of Melanoma 
 The limited treatments available for melanoma patients in the mid-late 19th 
century included ligature, chloride of zinc, amputation, surgical excision with a scissor or 
knife, or the use of caustic agents to burn the tumor away. Fortunately, surgical 
anesthesia first became readily available in this time frame as well, with a report in the 
Lancet from 1851 reporting the excision of a melanoma from a 45-year old woman of “melancholy appearance…rendered insensibly by chloroform” [18, 19]. Herbert Snow, a 
London surgeon, is known as the “original champion of elective lymph node dissection 
in melanoma [20]. In 1892, Snow strongly supported melanoma patients being treated 
by excision and anticipatory gland excision because he did not believe the removal of 
the primary melanoma alone to be effective [21]. He was quoted stating “it is essential 
to remove, whenever possible, those lymph nodes which first receive the infective 
protoplasm” [21]. Snows surgical practices were viewed controversial and radical, as 
elective lymph node dissections were not accepted at that time [20].   
 The surgical protocol for melanoma patients continued to evolve with the aid of 
Scottish physician William Handley. Handley developed expertise on cancer metastases 
from studying the metastatic dissemination of breast cancer while a research fellow at 
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the Middlesex Hospital, London [22]. In 1905, Handley studied the lymphatic spread of a 
secondary melanoma deposit on a woman’s leg and subsequently suggested the 
excision of ~five cm of subcutaneous tissue down to the level of muscle fascia and the 
radical removal of lymph nodes [22]. Handley published his work in the Lancet in 1907, 
ultimately developing a concept that helped guide the surgical treatment of melanoma 
for nearly half a century. In 1908, the surgeon Pringle considered Handley’s seminal 
work describing melanoma’s lymphatic spread, and adopted the protocol of ‘excision 
and dissection in continuity’ [22]. Excision included the site of primary melanoma, as 
well as close proximity lymph nodes and an extensive region of skin, subcutaneous fat 
and fascia between the original lesion and regional tumor positive lymph nodes [13, 22].  
 The 19th century observations proved vital to defining melanoma as a distinct 
disease, however little insight into the etiology and mechanistic basis of melanoma was 
learned. It was not until the late 20th century where melanoma prognosis and effective 
treatment methods were defined, thanks largely to the careful observations and rigorous 
quantitative methods of Wallace Clark and Alexander Breslow. In 1966, Clark studied 
histological examination of melanoma patients and developed a standard scale to 
assess the prognosis of melanoma [23]. The system, called Clark’s levels, divided the 
extent of downward invasion into five levels of the skin and subcutis. Each consecutive 
level was deemed more deadly as the tumor cells invaded deeper into the epidermis, 
dermis and subcutaneous tissue. Also of merit, Clark debunked the earlier assumption 
that all melanomas were descended from nevi in a set of 209 cases showing only 9.6% 
had the indisputable presence of nevus cells.  
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In 1970, Breslow expanded on Clark’s observations and noted prognosis of 
cutaneous melanoma appeared to be a function of both tumor size and level of 
invasion, and tumor thickness was the most significant measure of size. The ground 
breaking work of Clark and Breslow is still relevant to this day in stratifying patients for 
prophylactic lymph node dissection [24]. Improvements in histopathologic 
prognostication have led to improvements in the surgical management of localized 
melanoma. With the discoveries of Clark and Breslow, it became clear to surgeons that 
the five cm margins advocated by Handley were unnecessary [25]. A series of 
randomized, prospective clinical trial supported the efficacy of narrower margins of 1 cm 
for thin melanomas, and 2 cm for thicker melanomas. Prophylactic lymph node removal 
was also discarded and replaced by the novel technique developed by Donald Morton 
of sentinel node biopsy, as a minimally invasive way to stage the regional nodes and 
prevent node dissection from those without metastasis [26, 27]. Currently, genetic data 
is being seamlessly integrated with histopathological observations to delineate how 
oncogenic drivers modulate pathological behavior. However, our genetic understanding 
of melanoma is yet complete, and our best treatment strategies still result in relapse and 
the onset of resistance in the majority of patients.      
 
Non-Surgical Management of Melanoma   
Once the melanoma has disseminated to distant organs and lymph nodes, little 
in the way of therapeutic benefit can be accomplished through surgery alone. Dr. 
Thomas Fawdington, an English physician from the Manchester Royal Infirmary wrote in 
1826 “	  As to the remote an exciting causes of melanosis, we are quite in the dark, nor 
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can more be said of the methodus medendi. We are hence forced to confess the 
incompetency of our knowledge of the disease under consideration, and to leave to 
future investigators the merit of revealing the laws which govern its origin and 
progress…and pointing out the means by which its ravages may be prevented or 
repressed”	   [14]. When Dr. Fawdington wrote these words, it was a time that predated 
our understanding of the nature of heredity, and the structure of DNA had not yet been 
discovered. Until only recently, many in the melanoma field felt Fawdington’s despair at 
having little therapeutic benefit to offer patients with widespread metastatic disease. 
With the exception of the last few years, the last forty years have shown no significant 
impact on survival, in spite of increased response rates achieved with combination of 
chemotherapeutics and/or cytokines such as IFN or interleukin-2 [28]. Thirty phase-III 
clinical trials resulted in increased toxicity and response rates, however did not improve 
survival compared to mono-chemotherapy with dacarbazine (DTIC) alone [28, 29]. 
Patients with advanced melanoma with metastases to distant sites have a very poor 
prognosis. Median survival time is 6-9 months and 3-year survival is 10-15% [29]. At 
present there are only a few effective treatments for the malignancy once it has 
disseminated, and appreciable clinical benefit has only been experienced in patients 
whose melanomas are BRAF mutant [2]. Promising results have been achieved with the 
use of immunotherapies such as PDL1 and CTLA-4 agonists, however, responders 
cannot be identified up front by any molecular or genetic features of the tumor or patient 
[30-32]. No targeted therapy regimen amongst the numerous tested have yielded 
appreciable improvement for overall survival (OS) of patients whose advanced 
melanomas are BRAF wild type, revealing a significant gap in our understanding of 
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what drives the survival of this subset of melanoma, as well as what critical pathways 
are being utilized to escape current therapeutic strategies.   
             
                    
Figure 1. Time line tracking the history of melanoma from the earliest 
recorded descriptions up to the present. 
 
 
 
Melanoma Incidence and Mortality 
Melanoma is the most aggressive form of skin cancer and its prevalence within 
the Caucasian population has significantly increased during the last few decades, being 
responsible for more than 75% of skin cancer deaths [33]. Approximately one person 
dies every hour from melanoma in the United States of America and it is estimated the 
year 2013 will bring approximately 76,690 new cases of melanoma of the skin and an 
estimated 9,480 deaths [33]. The high mortality rates associated with melanoma is 
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largely due to its aggressive nature and propensity to metastasize. Relatively small 
tumors, less than 2 mm thick still have the potential to spread throughout the body, 
largely due to the fact that melanoma cells are equipped with features needed to 
complete the metastatic process [34]. Melanoma incidence rates have been increasing 
quicker than any other cancer type in most developed countries since the 1950’s, and is 
the second most common cancer in people between the ages of 25-29 [35, 36]. This 
observation has partly been attributable to the popularity of tanning beds in the U.S. 
[37]. Unfortunately, melanoma strikes individuals in the prime of their lives with a 
median age of 52 years, almost a decade before most solid tumors arise, such as 
breast, colon and lung [33, 38]. Consequently, preventative and more effective therapy 
options are urgently needed due to the rapidly increasing incidence and highly 
aggressive, metastatic nature of melanoma.  
Early detection is vital with extremely promising five-year survival rates for 
patients whose melanoma is caught when localized to the organ of origin, at around 
95% [33]. Unfortunately, once the melanoma has extended into the surrounding organs 
or tissues, survival rates drop to 62% [33]. If the melanoma has spread to remote 
organs, tissues, or via the lymphatic vasculature to distant lymph nodes, it becomes 
increasingly difficult to adequately treat and survival rates drop precipitously to 15% 
[33]. Although there has been considerable progress made recently in the management 
of metastatic melanoma, significant improvement in overall survival has been difficult to 
achieve due to the high rate of metastasis in patients with advanced disease.   
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Melanoma Metastasis 
 The metastatic cascade in cancer involves a non-random, complex process 
where cancer cells detach from primary tumors, migrate and invade into the surrounding 
tissue, eventually intravasate into vasculature, circulate through blood or lymphatic 
vessels, extravasate from the circulation, and ultimately establish a metastasis in a 
distant tissue or organ [39, 40]. Melanoma is a highly aggressive and metastatic cancer 
with 75% of melanoma patients possessing disease dissemination to the brain, liver or 
lungs, amongst other organs upon autopsy [39, 41-43]. Once metastasis to the brain 
has been detected, melanoma patients suffer a median overall survival of ~4 months 
[39]. Critical to the homing of melanoma cells to various tissue and organs sites for 
metastasis are chemokines and their associated receptors. The ligand CCL27 has been 
reported to be constitutively secreted by keratinocytes and its associated receptor 
CCR10 is expressed within melanocytes, and further upregulated in mRNA and protein 
expression within melanoma cells [40, 44]. CCR10 has been shown to dictate selectivity 
of melanoma cells to metastasize to lymph nodes [45]. Studies have shown the utility of 
neutralizing antibodies directed against CCL27 in preventing metastasis in murine 
models, providing rationale for possible future therapeutic intervention to abrogate 
chemokine-mediated metastasis [40, 45]. Also observed with increased metastatic 
burden in melanoma is the expression of CD271, a marker shown to correlate with 
cancer stem cells (CSCs) [46]. 
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Melanoma Stem-like Cells 
 Melanocytes are derived from neural crest stem cells (NCSCs) and evidence is 
accruing in support of the existence of a subset of cells with “stem-like” features within 
melanoma tumors [47]. These stem-like cells are distinct from non-malignant stem cells 
in they have low proliferative rates, possess the propensity to differentiate into rapidly 
proliferating tumor cells and may confer observed clinical resistance to chemotherapy 
and targeted agents [48]. The stem cell markers CD133 [49], CD20 [50], CD271 [51] 
and the histone 3 K4 demethylase JARID1B [52] are expressed in subsets of slow-
cycling, treatment resistant melanoma cells with critical roles in long-term growth and 
escape from therapy. Strategies to inhibit melanoma cells expressing these markers 
resulted in impaired tumor initiation and reduced tumor growth, revealing the potential 
importance of therapeutically targeting these stem-like melanoma cells.  Dissection of 
gene networks shared by NCSCs and melanoma cells has revealed a critical role for 
Sox10 in determining cell fate decisions of NCSCs and melanoma cells [47]. Haplo-
insufficiency of Sox10 prevented the formation of melanoma without affecting other 
neural crest derivatives in an NRAS mutant melanoma model, suggesting another 
possible therapeutic target [53]. An in-depth biological understanding of how these 
proteins are utilized within this therapy-resistant subset of stem-like cells may provide 
insight on how to improve clinical management of metastatic disease in melanoma 
patients. 
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Predisposition to Melanoma 
The malignant transformation of melanocytes, the pigmented cells of the skin, 
leads to the development of melanoma [54]. Exposure to ultra-violet radiation has been 
proven to be etiologic, and the Australian mathematician Henry Oliver Lancaster first 
discovered its connection to melanoma in 1956 [55, 56] (Figure 1). He observed that the 
risk of melanoma development was directly associated with “latitude”	   or intensity of 
sunlight, and especially correlated amongst Caucasian populations [55]. A year later, 
Lancaster and Nelson demonstrated that 5 skin characteristics (skin color, texture, hair 
color and reaction to sun) were also of etiological importance in melanoma development 
[57]. The risk of developing melanoma was observed to be significantly increased in 
populations of English/Celtic ancestry (typically with pale skin and a poor tanning 
response) that migrated to areas of high ultra-violet exposure such as Australia or the 
southern United States (eg: Florida) [13, 57]. 
Investigators studying the genetics of mouse coat color led to the findings that 
both the tanning response and hair/skin color in humans was regulated through the 
ultra-violet mediated activation of a G-protein coupled receptor called the melanocortin 
receptor 1 (MC1R) [58]. Genetic polymorphisms in the MC1R contribute to fair skin, 
freckling and red hair due to inefficient cyclic adenosine monophosphate (cAMP) 
signaling stimulation upon ultra-violet exposure, leading to an impairment of melanin 
production in the skin, ultimately resulting in reduced photo-protection upon ultra-violet 
exposure [59-61]. Some of the earliest observations that melanoma could be heritable 
were made with the discovery of “melanoma families”	   where heritable germ line 
mutations led to an increased risk of melanoma developments from generation to 
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generation [62, 63]. About 5-12% of all melanomas are estimated to be hereditary [64]. 
40% of these hereditary melanomas are associated with CDKN2A mutations [64, 65]. 
CDKN2A encodes for p14ARF and p16INK, found to modulate cell cycle entry at the G1 
checkpoint and stabilize p53 expression [66]. Patients with CDKN2A mutations 
commonly exhibit multiple nevi and have a family history of melanoma. To date, at least 
178 melanoma families have been identified with CDKN2A mutations [62]. The 
melanocyte lineage specific microphthalmia transcription factor (MITF) is another gene 
recently found to predispose humans to melanoma through germline gain-of-function 
mutations [67]. Mechanistically, the MITF mutation was found to impair sumoylation and 
deregulated several MITF downstream targets [67]. Also of interest, if you contain more 
than 50 moles on your body your chances for melanoma are elevated [68] 
 
Targeted Revolution of Melanoma 
The realization that tumors arise following the acquisition of genetic mutations 
represented one of the most significant discoveries in our understanding of cancer 
biology. The first steps towards this path were taken in 1911 with the experiments of 
Peyton Rous, who showed that purified isolates from chicken sarcoma filtered through 
sand (to remove bacteria) induced primary sarcomas in young chickens [69, 70]. The 
work from Rous helped provide a foundation that eventually linked viral oncogenes to 
their normal human cellular gene counterparts. In 1977, Joan Brugge and Ray Erikson 
identified the viral gene v-Src as being responsible for the transforming function of the 
Rous Sarcoma Virus [71]. v-SRC was later shown to be a protein tyrosine kinase very 
similar to the same c-Src protein that was ubiquitously expressed in every human cell 
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[72]. These findings along with others lead investigators at the time to the idea that 
tumor development occurred following the acquisition of mutations in normal cellular 
genes, an era known as the “oncogene revolution”.  
A new family of oncogenes, the Ras genes, were discovered in the early 1980s 
and found to be quite different from previously characterized receptor tyrosine kinases 
(RTKs; such as PDGFR and MET) and non-receptor tyrosine kinases (such as Src), 
and were instead small GTPases that functioned as molecular switches linking cell 
surface RTKs to downstream signaling pathways [73, 74]. Activating NRAS mutations 
were initially identified within melanoma cell lines in 1984 and subsequently in 
melanoma patient cultures [75, 76]. It is now known that ~15-20% of all melanomas are 
NRAS mutant. Investigators were able to grow multiple cell lines from different lesions 
on the same patient, which gave the first indication that melanoma was a genetically 
heterogeneous disease [76]. Although Ras genes were discovered more than 30 years 
ago, effective strategies to therapeutically target these GTPases remain elusive [77]. Ulf 
Rapp cloned CRAF in 1983, which was found to be the human homologue of the mouse 
retrovirus M3661-MSV derived v-raf oncogene [78]. Closely related RAF family 
members ARAF and BRAF were subsequently discovered in 1986 and 1988, 
respectively [79, 80]. RAF genes encode for serine/threonine kinases that are important 
members of the mitogen activated protein kinase-signaling cascade 
(RAS/RAF/MEK/ERK) [81]. In 2002 a systematic genetic screen demonstrated the 
importance of RAF in melanoma when activating BRAF mutations were identified in half 
of human cutaneous melanomas [1]. 
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The Role of BRAF in Melanoma 
 The discovery that mutations in BRAF occur in ~50% of all cutaneous 
melanomas profoundly enhanced our understanding of melanoma biology. RAF 
proteins constitute a 3-member family of Serine/Threonine kinases (ARAF, BRAF and 
CRAF) with closely overlapping functions that make up part of the RAS/RAF/MEK/ERK 
MAPK signal transduction pathway [82]. No mutations have been described in ARAF or 
CRAF to date [83]. Of interest, a recent report uncovered a novel role for ARAF in 
serving as a stabilizing agent in BRAF/CRAF complexes in the context of RAF inhibitor 
treatment [84]. Although there exists more than 50 distinct mutations in BRAF 
described, the most common BRAF mutation, accounting for 80% of all BRAF 
mutations, is a valine to glutamic acid (V600E) substitution [85-87]. The acquisition of a 
V600E mutation in BRAF destabilizes the inactive kinase conformation, shifting the 
equilibrium towards the active form, leading BRAF V600E to be 500-fold activated and 
confer constitutive MEK and ERK signaling [85, 88]. There is now a wealth of evidence 
demonstrating mutated BRAF exerts most of its oncogenic effects through the activation 
of the MAPK pathway [89, 90], driving the uncontrolled dissemination, proliferation and 
survival of melanoma cells. The identification in 2003 of similar activating BRAF 
mutations in 80% of benign nevi helped solidify the link between nevi and melanoma 
that had been suggested by Norris in the 1800’s [12, 91]. Pre-clinical studies have 
shown the introduction of mutated BRAF into immortalized melanocytes leads to 
anchorage-independent growth and tumor formation in immunocompromised mice [90]. 
Also, downregulation of mutated BRAF using RNAi causes the reversal of the 
melanoma phenotype in both in vitro and in vivo BRAF V600E mutant melanoma 
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models, proving mutant BRAF as a major regulator of oncogenic behavior [81, 92-95]. 
All of the available evidence advocates that mutated BRAF is an ideal candidate for 
targeted melanoma therapy [96]. 
 
Clinical Development of BRAF Inhibitors 
 Melanoma presents itself as clinically and genetically distinct subsets, 
demonstrating the need for patient-specific diagnostic and treatment tools [97]. The 
identification of BRAF mutations in melanoma patients launched the development of a 
number of small molecule BRAF inhibitors that are now at various stages of clinical 
development. Sorafenib (BAY43-9006, Nexxavar) was the first putative BRAF inhibitor 
to be investigated in melanoma [98]. Sorafenib was originally developed for CRAF, but it 
was also shown to have some activity against BRAF and was the first kinase inhibitor 
available for evaluation in BRAF mutant melanomas [99]. Pre-clinical investigations, 
however, showed sorafenib to be a relatively weak inhibitor of BRAF, with many off-
target effects.  Animal xenograft studies revealed sorafenib treatment led to minor levels 
of regression in BRAF V600E melanoma and induced limited levels of apoptosis [99]. 
Following the evaluation of sorafenib, a new generation of highly specific and potent 
BRAF inhibitors has been developed and these drugs showed greater selectivity for 
mutant BRAF with fewer off-target effects [3]. The two BRAF inhibitors best studied in 
the clinical setting are PLX4032 (RG704, vemurafenib, Zelboraf) and GSK2118436 
(dabrafenib, Tafinlar) [100, 101]. PLX4032 was FDA approved in 2011 and 
GSK2118436 was FDA approved in 2013. Further success has been achieved from the 
combination of the MEK inhibitor trametinib and BRAF inhibitor dabrafenib in the 
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treatment for BRAF mutant melanomas in phase III clinical trials, resulting in the first 
combination therapy to be FDA approved for melanoma in 2013. Although there has 
been much success for the therapeutic options available for BRAF mutant melanoma 
patients, equivalent discoveries are urgently needed to treat those ~50% of all 
melanoma patients without activating BRAF mutations. 
 
The Role of RAS in Melanoma 
 Few advances, to date, have been accomplished developing targeted therapy 
modalities for the ~50% of patients whose melanomas are BRAF wild type. Among the 
cutaneous melanomas that are BRAF wild type is the subgroup of 15-20% of all 
melanomas that harbor NRAS (Neuroblastoma Rat Sarcoma Virus) mutations [102]. 
Ras genes were initially discovered as being responsible for encoding the proteins that 
allow for the transforming activity of the Rat sarcoma virus [74, 75, 102]. Ras proteins 
embody a large family of plasma membrane-associated GTP-binding proteins, which 
include NRAS, HRAS (Harvey Rat Sarcoma virus) and KRAS (Kirsten Rat Sarcoma 
virus) [74]. Approximately one-third of all human cancers have oncogenic mutations in 
the Ras family of small GTPases [103-105]. RAS functions as a GTPase intermediate 
between cell surface receptors and links upstream activation to pathways that regulate 
growth, cell cycle and survival [104, 106]. Under physiological conditions, a ligand 
binding to its cognate RTK results in RTK autophosphorylation and the recruitment of 
Grb2 adaptor molecules [107, 108] (Figure 2A). Grb2 binds to the RTK intracellular 
region via its SH2 domain and further recruits SOS (son of sevenless) to the plasma 
membrane via two SH3 domains [108]. SOS facilitates signal transduction to RAS by 
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catalyzing the exchange of a GDP for GTP, switching RAS from an inactive (GDP-
bound) state to an active (GTP-bound) state [109]. Activation of RAS through GDP to 
GTP exchange is mediated by a family of guanine nucleotide exchange factors (GEFs), 
that include RASGRF, SOS1 and SOS2 [102, 104]. GEFs accelerate GDP release by 
Ras, allowing more robust GTP binding and activation. The stimulating effects of GEFs 
are counter balanced by GTPase-activating proteins (GAPs), which promote a rapid 
rate of GTP hydrolysis, returning Ras to its inactive state. Once activated, RAS results 
in the recruitment and activation of a number of intracellular signaling cascades, which 
include the activation of RAF (ARAF, BRAF and CRAF) leading to MAPK pathway 
signaling, the PI3K-AKT pathway and Ral-GDS activity (Figure 2C) [110].  
Currently it is known that amongst melanoma patients, mutations occur in NRAS, 
KRAS and HRAS in 20%, 2% and 1% of cases, respectively [111]. For NRAS, the most 
common mutations occur at positions 61 and 12, and less frequently at 13 [103]. ~80% 
of the mutations involve Q61, a point mutation leading to the substitution of leucine to 
glutamine at position 61 [103]. In HRAS, the majority of mutations also occur at position 
61 and KRAS mutations occur mostly at position 12 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/). Mechanistically, mutations at position 
61 leads to defective GTPase activity, locking NRAS in its active state. This confers 
constitutive activity across downstream NRAS effector MAPK and PI3K/AKT pathways, 
which drive cellular transformation [103]. Mutations at position 12 and 13 confer 
immunity upon RAS from the inhibitory mechanisms of inactivation found under 
physiological conditions in non-transformed cells [104] (Figure 2B). Exactly why NRAS 
mutations are more prevalent in melanoma compared to HRAS and KRAS is unknown, 
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however NRAS mutations appear to have a greater transforming ability relative to 
HRAS and KRAS mutations, as seen in preclinical models of melanoma [112]. There 
are also observations that NRAS is overexpressed in melanocytes compared to other 
RAS isoforms [112].  
Interestingly, NRAS mutations have been found to occur during the earlier stages 
of oncogenesis, with evidence of NRAS mutations in 14% of benign nevi [91]. Although 
the majority of benign, common nevi possess BRAF mutations (~80%), no BRAF 
mutations have been observed in congenital nevi (nevi that develop in utero), and 
instead 81% were found to contain NRAS mutations [113]. As most nevi rarely progress 
to melanoma, it is suggested that mutations in NRAS are not all that is needed for 
initiation of melanoma, and other genetic events are required [102]. A parallel line of 
investigation leveraging genetically engineered mouse models (GEMMS) of melanoma 
designed to have HRAS or NRAS mutations observed that exposure to UV light or 
inactivation of the tumor suppressor p16INK4A was necessary for the initiation of 
melanoma [114, 115]. NRAS was found to inhibit p16INK4A through the methylation of its 
promoter [116]. The dependence of melanoma cells upon mutant NRAS was 
demonstrated by showing an inhibition of proliferation and invasion in NRAS mutant 
melanoma cell lines treated with small interfering RNA (siRNA)-mediated silencing of 
NRAS, which was associated with a reduction in cyclin D1 expression and the 
expression of cytoskeletal proteins paxillin and vinculin [117]. 
Signaling-wise, NRAS and BRAF mutations both signal through the MAPK 
pathway in subtly different manners. In non-transformed human melanocytes, growth 
factor stimulated activation of the MAPK pathway signals through BRAF rather than 
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CRAF. This RAS-isoform selectivity occurs due to the inactivation of CRAF from the 
relatively high expression of cyclic AMP in melanocytes [118-121]. In NRAS mutant 
melanomas, MAPK activation occurs through CRAF, in contrast to BRAF mutant 
melanomas signaling through BRAF [118]. NRAS mutant melanoma cell dependency 
on CRAF-mediated MAPK activity stems from a feedback inhibition mechanism from 
ERK, where ERK inhibits BRAF by phosphorylating it at Ser151, Thr401, Ser750 and 
Thr753 [122], which effectively blocks the dimerization of BRAF with CRAF. NRAS 
mutant melanoma cells also possess increased expression of the enzyme 
phosphodiesterase IV, which deregulates PKA signaling, allowing CRAF to remain free 
of inhibitory phosphorylation at its Ser43 and Ser233 residues [119].  
Clinically, NRAS mutant melanomas behave differently than BRAF mutated or 
BRAF/NRAS wild type melanomas. NRAS mutations are typically found in patients 
above the age of 55 and a history of chronic exposure to ultraviolet light, relative to 
patients whose melanomas are BRAF mutated [123, 124]. NRAS mutated melanomas 
are correlated with thicker tumors, higher mitotic rates and tend to localize at the 
extremities [123, 125]. Ultimately patients with NRAS mutant melanoma suffer 
significantly worse OS rates compared to patients without NRAS mutations, making 
NRAS mutational status an independent predictor of shorter survival from the diagnosis 
of stage IV melanoma [123, 126]. 
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Figure 2. Diagram of RAS signaling. (A) Physiological activation of RAS in non-
transformed cells. (B) RAS is locked in a GTP-bound, active confrmation when mutated 
in cancer cells. (C) A simplified diagram showing a few key effector pathways of RAS 
activity in melanoma cells. Active RAS  stimulates the MAPK pathway, the 
PI3K/AKT/mTOR pathway and Ral-GDS funtionality.  
 
 
 
Strategies to Inhibit RAS 
Pre-clinical studies have demonstrated melanoma cells harboring NRAS 
mutations are dependent on NRAS for their survival and proliferation, making NRAS an 
attractive target [75]. To date, targeted therapeutic strategies poised at inhibiting NRAS 
have had pre-clinical success, but these tactics have not translated much in the way of 
clinical activity [77, 127]. Developing specific inhibitors that directly target RAS has 
proven difficult, as RAS is a GTPase and does not rely on ATP for its activity as do 
kinases [127]. Developing ATP-competitive or allosteric inhibitors of MEK or BRAF has 
proven more clinically successful than attempts to block GTPase activity. Strategies to 
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target GTPase activity of NRAS directly have been attempted, however the 
accumulation of RAS-GTP, the high affinity of RAS for GTP, as well as the high 
concentrations of GTP in cells has made targeting GTPase activity of NRAS difficult 
[128] (Figure 3A).  
Another approach has involved targeting the Ras-membrane association, since 
Ras must localize to the membrane to become activated. RAS proteins have classically 
been described to localize at the inner face of the plasma membrane to allow for its 
interaction with upstream activators (RTKs) and downstream effector targets (MAPK 
and PI3K-AKT pathways) [127]. RAS has also been observed to reside within the inner 
membrane compartments of various organelles of the cell including the endoplasmic 
reticulum, Golgi and mitochondria [127, 129-131]. What is essential for RAS to function 
in any of the characterized locations of the cell is its membrane anchorage in these 
regions [105, 132]. Localization of RAS to the cell membrane is a complex biochemical 
process that involves post-translational modifications of RAS at its carboxy-termini. A 
hydrophobic lipid domain is added to a highly conserved carboxy-terminal CAAX motif, 
(C, cysteine; A, aliphatic amino acid; X, either S or M for H-, N- and K- RAS proteins) 
which facilitates membrane localization, known as farnesylation [133]. Farnesylation is 
catalyzed by the enzyme farensyltransferase (FTase) [134-136]. Since the farnesyl 
group of RAS has been established as a requirement for the ability of RAS proteins to 
transform cells, the field postulated that inhibitors of FTase represented the best 
therapeutic option to inhibit oncogenic RAS and has been extensively studies (Figure 
3B). Unfortunately, inhibiting FTase was not found to be particularly effective, and 
KRAS and NRAS have been observed to undergo further modification by the enzyme 
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geranyl-geranyl protein transferase -1 (GGTase-1) when FTase inhibitors were used 
[137, 138].  Attempts to target farnesylation have also proven ineffective in a number 
phase II and phase III clinical trials, despite pre-clinical studies showing some efficacy in 
FTase inhibitors to block oncogenic signaling of NRAS, and have been associated with 
serious off-target effects reported [128, 139, 140]. These observations are thought to 
have manifested due to other proteins that FTase normally modulates other than RAS. 
Nonetheless, intense research is ongoing in targeting the critical maturation processes 
that are required for RAS activity. Some of these additional processes and targets being 
investigated include inhibiting GGTase-1, palmitoyltransferase inhibitors, Rce1 inhibitors 
and farnesylthiosalicylic acid [141, 142].   
Instead of targeting the maturation steps required for NRAS function, simply 
extinguishing the expression of NRAS with the use of Interfering RNAi has shown pre-
clinical efficacy (Figure 3C). RAS knockdown has been shown to be achievable in vitro 
using either antisense oligonucleotides or siRNAs, however there has been a failure in 
translating these strategies to the clinical stage, largely because of delivery 
complications and stability issues of nucleic acid molecules in the circulation [117]. 
Research is now focused upon leveraging nanoparticle-based delivery strategies to 
improve siRNA delivery in vivo [102, 143]. 
 Given the dependence on MEK and ERK signaling for a portion of the biological 
effects of Ras, a simpler therapeutic paradigm would be to inhibit MEK and/or ERK 
activity in NRAS mutant melanoma, a strategy that is currently being investigated in the 
clinic. (Figure 3D, E). Pre-clinical studies have demonstrated that melanoma cells with 
NRAS mutations display a spectrum of sensitivity toward MEK inhibition, with some 
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extremely sensitive and others demonstrating near-total resistance [96, 144, 145]. 
Fortunately, MEK inhibition has shown clinical activity in patients whose melanomas 
harbour NRAS mutations [146]. Fitting with mutant NRAS capable of activating the 
PI3K/AKT pathway, in addition to MAPK signaling, recent reports have shown 
enhancements in the pre-clinical activity of MEK inhibitors in NRAS mutant melanoma 
cells when combined with PI3K/AKT/mTOR pathway inhibiting agents [147], and 
multiple clinical trials are currently evaluating this combination (BEZ235/MEK162, 
BKM120/MEK162, MSC1936369B/SAR245409). A recent report shed light on p21-
activated kinase-1 (PAK1), a novel potential driver of and therapeutic target in BRAF 
wild type melanomas, to play functional role in proliferation and migration [148, 149]. 
High PAK1 protein expression was found in 27% of melanomas, focal copy gains of 
PAK1 at 11q13 were observed in 9% of melanomas, and there was a negative 
association with BRAF mutations [150]. Although numerous combination trials are 
underway, the most effective combination treatment for patients whose melanomas 
harbor NRAS mutations remains to be found. 
 
The Role of MEK in Melanoma 
 As ~65-70% of all melanomas possess mutations that hyperactivate the MAPK 
signaling pathway, there has been much interest in targeting the downstream 
component MEK in an attempt to effectively inhibit this signaling axis. The mitogen-
activated extracellular signal-regulated kinase (MEK) pathway represents one of the 
most characterized signaling cascades in all cell biology.  
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Figure 3. A diagram displaying strategies to target mutant RAS. Targeting GTP 
association to RAS (A), membrane localization via FTIs (B), mutant RAS directly with 
nucleic acids (C), and downstream MAPK pathway activity by targeting MEK (D) and 
ERK (E) are a few of the strategies employed.  
 
 
It has been recently reported that has high as 8% of all melanomas harbour recurrent 
somatic mutations in MAP2K1 and MAP2K2 genes, which encode MEK kinases [151]. 
Activation of the MAPK pathway can be triggered from a number of different 
mechanisms, which include growth factor binding to their cognate receptors, activating 
RAF mutations, RAS mutations and MEK mutations. Constitutive activation of the RAS-
RAF-MEK-ERK signaling cascade leads to enhanced proliferation, angiogenesis, 
cancer cell differentiation and survival [152] and as high as 90% of all melanomas show 
constitutive pERK activity [83]. Whether a cell is non-transformed functioning under 
normal physiological conditions, or has a mutation in either BRAF or NRAS, the 
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upstream activation of the pathway leads to the RAF-mediated phosphorylation of 
MEK1 and MEK2 on two adjacent sites in the activation segment (Ser218 and Ser222) 
[153-156]. Other kinases have also been discovered capable of 
phosphorylating/activating MEK, including PAK1 and COT [155]. The activation of 
MEK1/MEK2 leads to the subsequent phosphorylation of ERK1 and ERK2 on Thr202 
and Tyr204 [156]. MEK1 and MEK2 are tyrosine and serine/threonine dual-specificity 
kinases and although no other known targets beyond ERK proteins have been 
characterized, activation of MEK regulates the downstream activity of more than 600 
nuclear and cytoplasmic targets [152, 153, 156, 157]. The mechanism of signal 
transduction in the MAPK pathway is structured as a three-tiered kinase module, which 
allows for powerful signal amplification, increasing intensity of pathway activity as the 
signal progresses down the axis [158, 159].  
Since the overwhelming majority of melanoma cells have aberrant activation of 
the MAPK pathway and the inhibition of RAS has proven difficult with currently available 
approaches, strategies have focused upon targeting RAF and MEK, most recently even 
ERK, the downstream effector of the pathway. Although much success has been 
achieved with the use of BRAF inhibition in melanomas with activating BRAF mutations, 
these BRAF inhibitors cannot be used in BRAF wild type cells with constitutive MAPK 
activity. The reason patients with BRAF wild type melanomas do not experience the 
same therapeutic benefit as those with BRAF mutant tumors utilizing BRAF inhibitor 
treatment results from the induction of paradoxical BRAF/CRAF signaling, which leads 
to hyperactivation of ERK [160]. The mechanism was found to be mediated by BRAF 
inhibitors binding to the ATP-binding site of one kinase in a dimer of RAF homodimers 
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(CRAF-CRAF) or heterodimers (CRAF-BRAF), which leads to the inhibition of one 
protomer while trans-activating the drug-free protomer [160, 161].    
Since patients with NRAS mutant melanoma cannot benefit from MAPK pathway 
inhibition in the way of direct RAS or RAF inhibitors, the scientific community has now 
focused upon targeting the next node in the MAPK signaling pathway, MEK. Multiple 
clinical trials have been launched to investigate the utility of using MEK inhibitors in this 
genetic subgroup of melanoma. One such trial was a phase-II trial with the third-
generation MEK inhibitor MEK162 in advanced cutaneous melanoma patients with 
BRAF V600 or NRAS mutations [146]. 30 melanoma patients with NRAS mutations 
treated with MEK162 showed promising clinical activity with an overall response rate of 
21% and a median progression free survival of 3.6 months, representing the first 
targeted therapy to show activity in patients with NRAS-mutant melanoma [146, 162]. 
Although MEK162 showed clinical activity, no complete responders and only a few 
partial responders were reported [162]. The evolving lesson of using small molecule 
BRAF inhibitors in patients with BRAF V600E mutant melanoma hints that resistance 
will always limit response to single agent therapy and that multi-drug combinations are 
necessary [163]. Resistance can often occur though depression of feedback inhibition 
and compensatory upregulation through parallel pathways. Feed back loops have been 
demonstrated to play a critical role in blunting BRAF inhibitor efficacy in BRAF mutant 
melanoma cells [164], weakening of single agent AKT inhibitor efficacy in a wide 
spectrum of tumor types [165] and dampening MEK inhibitor potency for the treatment 
of triple-negative breast cancer [157]. Adaptive signaling loops have been poorly 
characterized in NRAS mutant melanoma cells undergoing targeted treatment. 
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Understanding the most important feedback loops in response to treatment will be 
critical for designing proof-of-principle clinical trials that effectively improve patient 
outcome. 
 
Resistance to MEK Inhibition 
 A recent report shed light on how cells may escape MEK inhibition through the 
rapid remodeling of the kinome, and increased activation of multiple RTKs (VEGFR2, 
PDGFRβ, AXL and HER3) [157]. Utilizing a quantitative proteomics approach, MEK 
inhibition was found to cause a short-term loss in pERK activity that was associated with 
a rapid degradation of c-Myc [157]. c-Myc expression is stabilized when phosphorylated 
by ERK at its Ser62 residue, and acts as a repressor on the transcription site for 
multiple RTKs, including PDGFRβ [166-168]. In the context of MEK inhibition, pERK 
loses its activity and is no longer capable of phosphorylating c-MYC, which results in its 
rapid degradation. This MEKi-mediated loss of c-MYC expression disrupts Myc-Max 
transcriptional repression and results in the induction of various RTKs [166]. RTKs have 
proven to play an important role in the escape of tumor cells from various cancer types, 
however successful implementation of RTK inhibitors in the clinic for melanoma has 
lagged due to poor characterization. 
 
Receptor Tyrosine Kinases In Cancer 
 RTKs play critical roles in the initiation, progression and escape from therapy in a 
variety of human cancers [169]. RTKs make up a large family of trans-membrane 
proteins that become activated when cognate ligand binds to their extracellular domain 
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[107]. There are fifty-eight known RTKs in the human genome, which are organized by 
amino acid sequence identity and structural similarities into 20 families [169]. Although 
there is a large structural assortment of extracellular domains found across RTKs, they 
all share similar molecular architecture and possess highly conserved intracellular 
domains [169]. Ligand binding causes receptor dimerization and downstream activation 
of associated signaling pathways, allowing RTKs to regulate a variety of cellular 
processes, including proliferation, growth, differentiation and survival. The 
overexpression of growth factors and RTKs is an event frequently observed in cancer, 
allowing for constitutive activity of downstream pathways via autocrine/paracrine loops 
[169-171].  
Therapies directed against RTKs are effective in many cancer sub-types, 
including cetuximab in EGFR-positive colorectal cancer [172], and trastuzamab for Her-
2 positive breast cancer [173]. Unfortunately the importance of some RTKs remains 
poorly understood in melanoma. Melanoma cell lines and tumor specimens have been 
shown to express a large number of RTKs, all with the potential to aid in escape from 
therapy [174, 175]. There is some clinical data showing efficacy of imatinib in melanoma 
patients with mutationally activated KIT [176] and pre-clinical data showing targeting of 
MEK and IGF-1R may inhibit melanoma cell proliferation and survival [177]. Recent 
preclinical discoveries have defined a survival function for RTKs in the escape of 
melanoma cells from targeted treatment. In BRAF mutant melanoma cells resisting 
BRAF inhibitor therapy, it has been demonstrated that acquired resistance can occur 
through increased levels of PDGFRβ [178] [179], IGF-1R [177] and c-MET [180] activity. 
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A recent report identified an association of activated c-MET and NRAS mutant 
melanoma, establishing rationale for further investigation [30].  
 
The Role of c-MET in Melanoma  
 c-MET is an RTK that has emerged as an important mediator in the development 
and progression of various breast and bladder carcinomas, osteosarcoma and 
melanoma [181]. Discovered in the 1980’s from the study of a human osteosarcoma 
tumor cell line, c-MET plays a critical role in the normal physiological tissue 
regeneration and embryonic development [182]. Several independent investigations 
have determined the only known ligand of c-MET to be hepatocyte growth factor (HGF), 
also known as scatter factor [183, 184]. HGF induces proliferation and increases 
mobility of liver cells [185-187]. HGF is primarily secreted by mesenchymal cells and 
activates cells of epithelial origin, as well as endothelial cells, neuronal cells and 
melanocytes, all possessing c-MET expression, in a paracrine fashion [188]. Over 
active c-MET signaling can occur through multiple mechanisms, including gene 
amplification, autocrine activation, overexpression of its ligand HGF and mutational 
activation of c-MET in its kinase domain [189-191].  
 Structurally, c-MET exists as a disulfide-linked heterodimer composed of an 
extra-cellular α chain and a longer β chain [181]. The β chain bridges the extracellular 
HGF-binding domains of c-MET, to the intracellular tyrosine kinase domains and 
multifunctional binding domains involved in downstream signaling cascades. HGF is a 
member of the serine protease family and initially exists as an inactive, single-chain 
precursor requiring further proteolytic conversion into an active heterodimer [181]. A few 
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proteases can activate HGF, including plasma kallikrein, hepatocyte growth factor 
activator and coagulation factor Xia [181, 190]. After cleavage, HGF can bind to the 
Sema domain of c-MET, inducing receptor oligomerization at the plasma membrane 
and autophosphorylation of the activation loop located in the intracellular kinase domain 
[191]. The autophosphorylation at tyrosines 1234 and 1235 causes the destabilization of 
the activation loop and allows the subsequent phosphorylation within the carboxy-
terminal-domain that ultimately functions as the multifunctional docking sites for multiple 
signaling adaptors [181].  
 The phenotypic effects from c-MET activation differ relative to cellular context 
and can give rise to a host of different cellular behaviors. The main signaling pathways 
that are modulated by c-MET are the RAS-MAPK and PI3K-AKT, along with other 
downstream effectors such as STAT3 and β-catenin [181, 188, 189]. The aberrant 
activation of c-MET signaling cascades is shown to play an important role in the escape 
of melanoma cells to therapy [180, 191]. c-MET has been reported hyperactivate in the 
invasive front of tumor cells, and is correlated with aggressive and invasive melanomas 
[30]. In BRAF mutant melanoma cells, an extensive investigation was carried out to 
characterize growth factors or secreted proteins that served critical functions in the 
escape from BRAF inhibitor therapy [180]. An analysis of over 20 factors revealed that 
HGF had the greatest protective effect in BRAF mutant melanoma cells resisting 
PLX4720 treatment [180]. Although there has been a great amount of preclinical data 
showing c-MET-conferred survival benefits for BRAF mutant melanoma cells treated 
with BRAF inhibitors, an investigation into the clinical relevance of c-MET expression on 
overall survival in patients with BRAF (V600E/K) advanced melanoma yielded 
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inconclusive results [192]. Further analyses must be carried out with greater patient 
numbers to see whether c-MET does have a clinically important escape function for 
BRAF mutant melanoma cells.  
 A report in 2012 uncovered that c-MET may also play an important role in the 
survival of melanoma cells harboring NRAS mutations [30]. In a cohort of melanoma 
clinical specimens, high expression of phosphorylated (activated) c-MET was observed 
in NRAS-mutated and BRAF/NRAS wild type specimens relative to BRAF-mutated 
samples. Further, inhibition of mutant NRAS was observed to decrease c-MET total 
protein expression, suggesting mutant NRAS to play a role in the stability of the RTK. 
NRAS-mutated melanoma cells were also more sensitive to inhibition of -MET relative 
to their BRAF-mutated counterparts, providing rationale for the further investigation in 
targeting c-MET for therapeutic efficacy in NRAS mutated melanomas.  
 
The Role of PDGFR in Melanoma 
Platelet-derived growth factor receptors (PDGFRs) have been recently implicated 
in melanoma survival in the context of acquired resistance to BRAF inhibition[178]. The 
interest for platelet-derived growth factor (PDGF) in cancer research emanates from the 
realization that the v-sis oncogene of simian sarcoma virus is a retroviral homolog of the 
cellular gene encoding the B chain of PDGF [193-196]. PDGFs were first identified as 
products of platelets, which stimulated the proliferation in vitro of connective tissue cell 
types such as fibroblasts, smooth muscle cells, and glial cells [197, 198]. PDGF is a 
four-member family of structurally related polypeptide units (A, B, C and D) that can 
form five functional homo- or hetero-dimer growth factors capable of activating two 
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tyrosine kinase receptors: PDGF α-receptor and β-receptor [199]. Studies have 
provided evidence that transformation of cultured cells by the sis oncogene is mediated 
by an autocrine PDGF-BB-like growth factor [193]. The active PDGF molecule is a 
30kDa dimer [200] consisting of two polypeptide chains linked together by disulfide 
bonds. PDGF activates PDGF receptors through the generation of PDGF dimers where 
each chain of the PDGF dimer binds one receptor molecule [198]. Ligand binding 
induces receptor dimerization, creating receptor homo- and heterodimers [201]. 
Dimerization is accompanied by receptor autophosphorylation in trans on multiple 
tyrosine residues in the intracellular region, creating binding sites for intracellular signal 
transduction molecules containing one or two copies of Src homology 2 (SH2) 4 
domains [202]. Receptor autophosphorylation serves to regulate the kinase activity and 
also create binding sites on the receptor molecule for downstream signaling 
components. Eleven autophosphorylation sites have so far been identified in the PDGF 
β-receptor and they are spread out across the transmembrane, juxtamembrane, kinase 
domain, and carboxy-terminal tail regions [202, 203]. PDGF-BB has a broad range of 
target cells, including mesoderm-derived cells pericytes and mesangial cells, and also 
ectoderm-derived glial cells and neurons [204]. PDGF-BB and the PDGF β-receptor are 
mainly expressed in the developing vasculature. PDGF-BB is produced by endothelial 
cells and it activates PDGF β-receptor expressing mural cells, including pericytes [204]. 
Most types of solid tumors produce PDGF-BB and PDGF receptor signaling participates 
in a variety of cellular processes ranging from stimulation of angiogenesis, autocrine 
promotion of tumor growth and recruitment of tumor stromal fibroblasts [204]. It comes 
as no surprise that PDGF-BB producing tumors are characterized by increased pericyte 
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abundance and accelerated tumor growth [204]. Knockout studies of PDGF-B or PDGF 
β-receptor resulted in pericyte deficiency of the microvasculature as a main phenotype, 
causing lethal hemorrhage at late gestation [199, 205]. 
PDGFRs are frequently overexpressed in a number of cancers, and their 
expression has been associated with tumor invasiveness, poor clinical outcome and 
resistance to therapy [199, 206]. PDGFRβ has been reported to play a role in the 
escape of melanoma cells from BRAF inhibitor therapy [178], and targeting the RTK-
PI3K-AKT-mTORC axis with PI3K and mTORC1/2 inhibitors triggered a significant 
apoptotic induction [179]. A report in 2013 found PDGFRα mutations in ~4.6% of 
melanoma patients [207], and further showed melanoma cells harbouring these 
mutations were sensitive to TKI’s imatinib and crenolanib. Combinatorial trials are 
currently underway investigating the utility of agents with activity against PDGFR in 
melanoma.  
 
The Role of AXL in Melanoma 
 AXL was recently found to be overexpressed in NRAS mutant melanoma cell 
lines, respective to NRAS wild type cells, and played a functional role in migration and 
invasion of tumor cells [208]. AXL (also known as Ark and Ufo) belongs to the RTK 
subfamily called TAM, which was identified in 1991 and includes Tyro-3 (Shy) and Mer 
[107]. TAM receptors were grouped together into one family as they all contain a 
combination of 2 immunoglobulin-like domains and dual fibronectin type III repeats in 
their extracellular domains [107]. The principle ligand for TAM receptors is a large (75 
kDa) vitamin K-dependent protein called growth arrest-specific 6 (Gas 6) [209]. AXL 
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was initially discovered as an unidentified transforming gene in 2 patients with chronic 
myelogenous leukemia (CML) in 1988, and was later cloned from other patients with 
CML [210]. AXL was named after the Greek word anexelekto meaning “uncontrolled” 
and the gene for AXL is located on chromosome 19q13.2 [210]. The expression of AXL 
has been observed in various organs and cell types within the body, which include the 
cerebellum, macrophages, platelets, liver and testis [211-213]. AXL overexpression has 
been reported in a number of cancers including esophageal [214], thyroid [215], breast 
[216] and recently in NRAS mutant melanoma cell lines [208]. AXL has been 
demonstrated to be frequently highly expressed in NRAS melanoma cell lines, as well 
as melanoma patient specimens, relative to their BRAF mutant and BRAF/NRAS wild 
type counterparts. High AXL expression was identified in 22/58 melanoma cell lines 
[208]. Upon categorizing the cell lines by mutation, it was noted that 70% of NRAS 
mutant tumor cells were AXL positive [208]. Its role appears to be centered on the 
invasive and migratory phenotypes of melanoma cells where inhibition of AXL has been 
associated with a cytostatic effect [208, 217].  
 Signaling pathways downstream of AXL include the PI3K/AKT and MAPK 
pathways [218]. No activating mutations in AXL, or any other TAM receptors, have been 
reported to aid in the development of cancer. Interest has grown in the way of 
developing small molecule inhibitors against AXL, which are at various stages of drug 
development. However, at the moment there are no compounds that specifically target 
AXL in the clinical stages of development [107]. The pre-clinical and clinical evidence 
suggests that targeting the AXL/Gas6 signaling axis may effectively inhibit metastatic 
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behavior of NRAS mutant melanoma cells and can possibly enhance response to 
chemotherapy or targeted agents [217].   
 
BRAF/NRAS Wild Type Melanoma 
 The remaining 25-30% of melanomas with neither BRAF nor NRAS mutations 
have largely unknown driver mutations. Lack of identified driver mutations in this 
subgroup suggests that our genetic comprehension of melanoma remains incomplete 
[219]. Multiple groups have observed that cutaneous melanomas possess significantly 
higher mutation rates compared to nearly all other solid tumors [219-222], and that 
much of this can be attributable to UV-exposure [56]. A melanoma discovery set of 21 
BRAF/NRAS wild type melanoma tumors was recently screened for genes that were 
mutated in at least 25% of these samples and ranked among the top fifty genes by 
functional mutation burden [219]. Loss of function mutations in the NF1 were observed 
in as many as 25% of these tumors, compared to only 2% in melanomas with either 
BRAF or NRAS mutations. NF1 is a tumor suppressor gene that codes for 
neurofibromin protein, involved in the inhibition of RAS-MAPK pathway activity [223]. It 
is hypothesized that since NF1 is a regulator of RAS signaling, perhaps inactivation of 
NF1 may provide a route for BRAF/NRAS wild type melanomas to possess aberrant 
MAPK pathway activation [219]. In addition to the NF1 mutations, an activating HRAS 
G13I mutation, activating CRAFE478K mutation and two MAP2K1 mutations were 
observed in the BRAF/NRAS wild type discovery set [219]. These additional mutations 
were found in melanomas that lacked NF1 mutations. Recent studies demonstrate 
PI3K-AKT signaling axis hyperactivation in as high as ~77% of all metastatic 
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melanomas, regardless of BRAF/NRAS genotype, providing a possible avenue for 
targeted therapeutic intervention in a melanoma subgroup with no other obvious targets 
[224].  
 
AKT Pathway and Melanoma 
 Activation of the MAPK kinase pathway does not account for all aspects of 
melanoma progression and it is becoming increasingly clear that other signaling 
pathways may be equally as important. The most studied of these is the PI3K 
(phosphatidylinositol 3-kinase)-AKT pathway. The hyperactivation of the PI3K-AKT 
pathway is one of the most frequent events occurring across all cancer types. AKT is a 
critical regulator of essential cellular processes such as proliferation, protein translation, 
autophagy and survival [225]. The significant proportion of MAPK pathway mutations in 
melanoma and the clinical activity of BRAF and MEK inhibitors implicate the importance 
of RAS-RAF-MEK-ERK signaling in the aggressive biology of melanoma, however the 
high rates of BRAF mutations and NRAS mutations found in benign nevi suggest 
activation of the MAPK pathway alone is not enough to explain the pathogenesis of 
melanoma [224]. Reports have shown the loss of the negative regulator of PI3K/AKT 
signaling, PTEN, allows BRAF mutated melanocytic nevi to escape oncogene-induced 
senescence and form tumors [226]. Further, loss of PTEN also confers resistance to 
BRAF mutant melanoma cells treated with BRAF inhibitor therapy pre-clinically [95] and 
clinically [227], with patients expressing PTEN experiencing improved overall survival 
compared to patients whose melanomas have lost PTEN expression. Further, the 
activity of AKT has been observed to increase with the progression of melanoma. High 
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AKT was observed in 17% of normal nevi, 43% of dysplastic nevi, 49% of primary 
melanomas and 77% of melanoma metastases [224]. Patients with high AKT activity 
experience far worse OS compared to patients with low AKT activity.  
Activation of the PI3K/AKT signaling axis in melanoma occurs through either 
paracrine/autocrine growth factors binding to RTKs and G protein-coupled receptors 
(GPCRs) or the binding of RAS proteins to GTP. The loss of expression and/or mutation 
of negative pathway regulators, such as PTEN can also confer constitutive activity of 
the PI3K-AKT axis. These activating signals result in the catalytic activity of PI3K, which 
forms a heterodimer consisting of a p85 regulatory subunit and a p100 catalytic subunit 
[224]. It is recruited to the membrane upon the activation of receptor tyrosine kinases 
and associates with adaptor proteins that bind to the SH2 domain of the p85 subunit 
[228]. RAS can also recruit and activate the p110 domain to the cell membrane [103, 
104]. PI3K exists in multiple isoforms with type 1A PI3K being the most frequently 
mutated in cancer [229]. After membrane recruitment and activation, PI3K 
phosphorylates PIP2 to PIP3, leading to the recruitment of down stream serine-
threonine kinases AKT and PDK1 [230] (Figure 4). PDK1 phosphorylates AKT at 
Threonine 308 and mTORC2 phosphorylates AKT at serine 473 for full activation of 
AKT [230].  
 The AKT family consists of three members AKT1, AKT2 and AKT3. Each family 
member exhibits different expression patterns depending upon cell type. Of these family 
members, 43-50% of melanomas have selective constitutive activity in AKT3, and with 
evidence that overexpression of AKT3 occurs as a result of copy number increases in 
the long arm of chromosome 1 [229]. Intimately linked to the PI3K/AKT pathway is the 
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mammalian target of rapamycin (mTOR) pathway. Activation of the mTORC1 signaling 
complex leads to the phosphorylation of S6 kinase and 4E-BP1, ultimately resulting in 
increased protein translation and proliferation [224, 229, 231, 232]. Importantly, AKT 
activity has also been observed to confer considerable resistance to melanoma cells 
treated with various agents including chemotherapeutics, radiation and MAPK inhibitors 
[95, 224, 229, 233-235]. For these reasons, rational combinatorial trials with AKT 
inhibitors are ongoing to maximize clinical benefit [236]. In addition to regulating the 
survival mechanisms mentioned above, the PI3K/AKT/mTOR signaling cascade is also 
know to regulate autophagy [237]. 
 
Autophagy 
 The pathogenesis of cancer can be influenced by a multitude of processes 
ranging from inflammation, differentiation, apoptosis, proliferation and metabolism [238]. 
It is critical we understand the cellular and molecular bases of these physiological 
processes to improve existing therapeutic modalities. Recent treatment strategies have 
focused upon targeting a homeostatic mechanism found within cells, known as 
autophagy, to improve existing therapeutic modalities [239-241]. Three major types of 
autophagy exist in mammalian cells (macroautophagy, microautophagy and chaperone-
mediated autophagy), however the best characterized in cancer is macroautophagy 
(from here on referred to as autophagy), a process that occurs at a basal rate in all 
eukaryotic cells to maintain intracellular homeostasis via recycling of non-essential 
components within the cell [237, 240-243].  
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FIGURE 4. Signaling scheme of the PI3K/AKT/mTOR axis. Once activated, AKT 
can stimulate NFkB, mTORC1 and p53 activity, and effectively modulate a vast array of 
biological processes, which include apoptosis, protein translation, autophagy and 
survival. 
 
 
The process involves the sequestration of damaged or misfolded proteins [244], 
engulfing of mitochondria (termed mitophagy) [245], and internalization of endoplasmic 
reticulum (amongst other cargo) into double membrane structures called 
autophagosomes. Autophagosomes are eventually fused with lysosomes (termed 
autolysosomes), resulting in the degradation of internal cargo and the release of 
essential building blocks for various macromolecules back within the cell to be recycled 
[246, 247]. A critical property to appreciate is autophagy comprises a highly dynamic, 
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multi-step process with multiple control points that can be positively or negatively 
modulated (Figure 5). The complexity in its regulation and activity dictates that its study 
be done carefully, as an accumulation of autophagosomes within a cell does not 
necessarily mean a treatment is inducing autophagy [246]. An accumulation of 
autophagosomes, as detected by transmission electron microscopy (TEM) or LC3 
lipidation on a Western blot, could reflect an induction of autophagy, a reduction in the 
degradation of autophagosomes [248, 249], or dysregulation in the proteins required for 
the transport of autophagosomes to the lysosome [250].   
Autophagosomes were first discovered through transmission electron microscopy 
(TEM) in the 1950s and thought to be pre-lysosomal structures (reviewed in [251]). 
Autophagy is evolutionarily conserved from yeast to mammals, and serves as an 
intracellular defense mechanism in cells to protect cells from a variety of different 
stresses. A multitude of environmental cues can trigger autophagy through regulatory 
factors that either activate or repress assembling of autophagic machinery [237]. The 
machinery of autophagy is tightly regulated and consists of several autophagy-related 
(ATG) proteins that choreograph the initiation, elongation, maturation and fusion stages 
of the pathway [237, 252, 253] (Figure 5). A major regulator of autophagy is the 
mammalian target of rapamycin (mTOR), which exists in a macromolecular complex 
termed mTORC1 [254]. Under conditions of nutrient or growth factor depletion, 
mTORC1 is inhibited and no longer able to repress the complex consisting of ULK1 
(UNC-51-like kinase 1), FIP200, ATG13 and ATG101 [246, 255]. When a cell has a 
toxic accumulation of damaged or unnecessary components, increased ROS levels, 
under starvation conditions or under the stress of certain treatments, autophagy is 
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increased to breakdown the damaged or unnecessary components of the cell into 
amino acids, monosaccharides and nucleotides, which are transported back into the 
cytosol for reuse by the cell [256, 257]. Autophagy occurs through a multi-step process 
including four control points. The first control point relies on the ULK1 (ATG1) kinase 
complex, which integrates stress signals from mTORC1 and controls the initiation of 
autophagy [253]. When autophagy is initiated, the cytoplasmic machinery is recruited 
onto phospholipid membranes derived from the endoplasmic reticulum and Golgi 
apparatus [253]. The second control point marks the beginning of autophagosome 
formation with the generation of signals on the surface of source membranes by class III 
PI3K, Beclin-1 and a host of other proteins [253]. The third control point allows for the 
maturation of autophagosomes and begins with the aid of ATG5 [246]. Conjugated 
ubiquitin-like protein light chain 3 (LC3) is conjugated to PE on the surface of 
autophagosome membranes, and LC3 is then lipidated to allow it to become integrated 
within the bilayer of the autophagosome [258]. Once lipidated, LC3 and Bif-1 aid in the 
curvature of the autophagosome and LC3 also recruits cargo adaptor proteins (p62), 
which recruit cargo from the cytoplasm and promote autophagosome closure [259-261]. 
The fourth and final control point allows for the delivery to lysosomes where their 
luminal and inner membrane constituents are broken down by lysosomal hydrolases 
[237, 240] (Figure 5). Lysosomal permeases allow the release of the degradation 
products into the cytosol for reuse by the cell. 
The role autophagy serves in cancer has been controversial, with observations 
demonstrating autophagy to suppress tumor development, while other reports showing 
a protective role of autophagy in established tumors [242]. Comparison of normal and 
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autophagy-deficient mice and cells has demonstrated a role for autophagy in the 
suppression of tumor development, where mice with autophagy defects accumulated 
ubiquinated keratins and abnormal mitochondria [262]. Defective autophagy resulted in 
an amassing of damaged cellular components linked to reactive oxygen species (ROS) 
production, activation of the DNA damage response and ultimately a chronic 
inflammatory state and cancer [263, 264]. Mice with allelic loss of Beclin-1, an essential 
autophagy gene for the beginning of autophagosome formation, display gross 
morphological tissue damage that is most striking where there is also an accelerated 
incidence of hepatocellular carcinomas [263, 264]. Another observation that therapy-
induced autophagy played a role in tumor cell cytoxicity demonstrated that a persistent 
induction of autophagy could lead to programmed cell death [265].These findings are 
significant because they suggest that autophagy stimulators may prevent both 
degenerative diseases and cancers arising from chronic tissue damage and 
inflammation.  
 Although autophagy can indeed suppress tumor development, it has been clearly 
demonstrated to also play a role in promoting the survival of existing tumor cells within 
the tumor microenvironment [266]. Autophagy induction has been associated with in 
vitro cancer cell death, but this may be due to a futile attempt of the cancer cells to 
survive through autophagy in the face of treatment-induced stress. These findings, 
none-the-less underscore the importance of interrogating the functional role of 
autophagy when autophagosomes are present. Autophagic cell death has been limited 
to in vitro conditions and has not manifested in vivo [266, 267]. The most prevailing and 
convincing evidence, however, is that in vivo, autophagy is induced by cellular stress 
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including nutrient, growth factor and oxygen deprivation [268]. And these in vivo 
inductions of autophagy function to maintain the survival of normal cells, mice and also 
tumor cells [269, 270]. When in vitro models incorporate stresses commonly 
encountered in vivo, autophagy’s contribution to cell survival becomes clearer. For 
example, autophagy-defective tumor cells undergoing metabolic stress showed 
impaired survival in comparison with autophagy-proficient cells [268].  
 The mechanism by which autophagy enables survival of normal or tumor cells in 
stress is not fully known. In oxidative stress, the autophagy-mediated clearance of 
damaged proteins and organelles may limit cellular damage and cell death through 
ROS production [257]. When nutrients are limiting, autophagy may promote viability by 
maintaining cellular metabolism through intracellular recycling. Regardless of how 
autophagy increases survival in stress, concurrent inhibition of autophagy may improve 
outcomes in cancer therapies. Cytotoxic cancer therapeutics induce autophagy, most 
likely by causing damage to DNA, cellular proteins and organelles [242]. Inhibition of 
autophagy with chloroquine in preclinical models improves the response of tumor cells 
to alkylating agents, suggesting that autophagy promotes survival [271, 272]. Ultimately, 
more than 10 clinical trials have been opened exploring the utility of autophagy inhibition 
in patients with refractory malignancies and this was made possible with reports that 
autophagy inhibition can be achieved in vivo with chloroquine [269].    
Chloroquine derivatives were originally used therapeutically for the treatment of 
malaria, as well as rheumatoid arthritis and HIV, for the last 60 years [273]. Chloroquine 
is a lysomotropic agent that localizes within lysosomes [246]. Once inside the lysosome, 
chloroquine becomes protonated, effectively trapping it within the lysosome, which 
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leads to the neutralization of the normally acidic lumen of the lysosome. The lysosomal 
acidic hydrolases are essential for the breakdown and digestion of autophagosomes 
and their internal cargo. Bisaminoquinoline autophagy inhibitors with 10 fold higher 
potency than hydroxychloroquine (HCQ) are also currently being characterized with 
hopes of having greater in vivo activity relative to previous autophagy inhibitors [274]. 
 
The Role of Autophagy in Melanoma   
 TEM has long revealed the existence of autophagocytic structures in melanoma 
lesions since the early 1980’s [275]. Genome-wide RNA interference screens have 
identified LC3A and Beclin-1 as part of 92 novel genes whose depletion interfered with 
the malignant transformation of normal melanocytes [276]. A recent study utilizing EM to 
assess the autophagic index in pre-treatment cutaneous biopsies of stage IV melanoma 
made the striking observation that patients experienced a reduction of 4 months in 
disease-free survival if their tumors contained more than 6 autophagic vesicles per cell, 
compared to patients with low level of autophagy activity [277]. Autophagy has been 
demonstrated to play a cyto-protective role in melanoma cells subjected to acidic 
conditions [278], nutrient deprivation [279] and the chemotherapeutic agent 
temozolomide [266]. Further, melanoma cell invasiveness correlates with high levels of 
autophagy, and the inhibition of autophagy with hydroxychloroquine or shRNA against 
ATG5 yield high levels of cytotoxicity [266]. Autophagy is shown to be elevated in 
primary melanoma tumors and correlates with lymph node metastases, suggesting a 
functional role for autophagy in the dissemination of melanoma [280, 281].  
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Figure 5. Signaling scheme of the 4 main stages of autophagy 
A large body of knowledge regarding the initiation of autophagy has been identified in 
the context of the mTOR pathway. mTORC1 negatively modulates the ATG1 complex. 
Nutrient deprivation leads to an inhibition of mTORC1 activity, relieving ATG1 of this 
inhibitory loop, allowing the ATG1 complex to favor nucleation. Here, PI3K III modulates 
the initiating phagophore, while interacting with Beclin-1 and other ATG proteins. ATG5 
regulates the maturation of the budding autophagosome and lipidated LC3 II (ATG8) is 
incorporated within the elongating autophagosome. Ultimately, the autophagosome 
(with cargo within its lumen) fuses to a lysosome, resulting in degradation by lysosomal 
hydrolases and recycling of breakdown products by the cell.   
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Another report observed treatment-induced autophagy to serve as an adaptive 
resistance mechanism in BRAF mutant melanomas escaping from BRAF inhibitor 
therapy [282]. This finding was of particular interest as the role autophagy plays in 
resistance to therapies that target PI3K/mTOR signaling have been well studied [283, 
284], however the function of autophagy in the context of MAPK pathway inhibition has 
not been well characterized. A phase I clinical trial is currently enrolling patients with 
BRAF mutant melanoma to investigate the utility of co-targeting autophagy and mutant 
BRAF (NCT01897116). Existing evidence encourages a more in-depth investigation of 
autophagy as a critical mechanism for melanoma drug resistance and maintenance. 
 
Discussion 
 Significant progress has been achieved for the treatment of melanoma since its 
identification as a disease in the early 19th century. Melanoma is now known to 
encompass a heterogeneous class of malignancies and can be stratified by mutational 
status of BRAF and NRAS. Once disseminated, little therapeutic benefit can be 
achieved from surgery alone, however advancements into the underlying genetic 
mutations driving disease progression have revealed therapeutic targets that have 
translated into clinical benefit. Though much of the recent success has been focused on 
patients whose melanomas harbor activating BRAF mutations, encouraging clinical 
activity has been reported with the use of MEK inhibitors in NRAS mutant melanomas. 
The discovery of loss of function NF1 mutations in BRAF/NRAS wild type melanoma 
and the observation of overactive AKT in the majority of melanomas may also provide 
future therapeutic avenues of success in this subgroup. 
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Chapter 2 
 Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when 
combined with paclitaxel and carboplatin in BRAF wild-type melanoma 
 
Introduction 
There has been immense progress in the development of targeted therapies for 
patients with metastatic melanoma. This approach has been clinically demonstrated 
through implementation of small molecule BRAF kinase inhibitors in individuals whose 
melanomas harbor activating BRAF mutations [285]. In randomized phase III clinical 
trials, treatment with the BRAF inhibitor vemurafenib is associated with significant levels 
of tumor shrinkage and a response rate of 48%, compared to 5% achieved with 
dacarbazine [2, 285, 286]. Small numbers of patients have been identified who show 
prolonged (>3 year) responses to single-agent BRAF inhibitor therapy, however 
resistance is nearly inevitable and arises in the majority of patients [82, 287]. 
Resistance to BRAF inhibitors is complex, multi-factorial, and typically dependent upon 
reactivation of the MAPK signaling pathway [82]. The functional role of MAPK pathway 
signaling recovery was demonstrated in phase III clinical trials where the combination of 
a BRAF inhibitor with a MEK inhibitor significantly increased progression-free survival 
compared to BRAF inhibitor alone [3, 164, 288].  
 Despite the significant improvements in systematic therapy for patients whose 
melanomas are BRAF mutant, few effective therapy options are available for the 50% of 
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melanoma patients whose tumors lack activating BRAF mutations. One significant 
group of BRAF WT melanoma, accounting for 15-20% of all cutaneous melanomas, are 
those harboring activating NRAS mutations (8, 9).  Highly potent allosteric inhibitors of 
MEK are currently being evaluated in NRAS mutant melanoma (10). In recent phase II 
clinical trials, the MEK inhibitor MEK162 was associated with a response rate of 20% in 
NRAS mutant melanoma with a median PFS of 3.6 months (10). Combination strategies 
for NRAS mutant melanoma are being actively explored, and will be the subject of 
discussion in chapters 3 and 4. The remaining 30% of all melanomas are wild type for 
both BRAF and NRAS and no obvious oncogenic drivers have yet been identified for 
this sub-group, despite intensive whole genome and whole exome sequencing efforts 
(11, 12). Novel strategies for targeting BRAF/NRAS WT melanoma are therefore 
urgently needed. 
 A large number of studies support a role for phospho-inositide-3-kinase 
(PI3K)/AKT signaling in the development and progression of melanoma (13). Upon 
activation, PI3K phosphorylates phosphotidylinositol-4, 5, biphosphate (PIP2) to PIP3, 
which in turn activates the downstream kinases PDK1 and AKT. Of these, AKT plays a 
critical role in survival through the phosphorylation of BAD as well as the regulation of 
cell cycle entry by phosphorylating and inactivating glycogen-3 synthase kinase 
(GSK3)-β, leading to the modulation of cyclin D1 (14, 15). PI3K/AKT signaling also has 
important downstream effects upon protein turnover and cell glucose metabolism via the 
regulation of the mTOR/S6K and GSK3β	  signaling pathways [224]. Despite single agent 
PI3K inhibition having little effect upon melanoma growth and survival, there is evidence 
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that PI3K targeted agents enhance the efficacy of MEK inhibition in both in vitro and in 
vivo studies (16-19). 
 Autophagy is an adaptive response to metabolic and drug-induced stress that 
involves the sequestration, lysosomal degradation and recycling of organelles and 
proteins (20).  Although the induction of autophagy constitutes an important mechanism 
of cell survival, persistent or high-level autophagy can lead to the depletion of key 
organelles and the activation of caspase-dependent apoptosis (20-22). In cancer, the 
role of autophagy is contradictory, with studies showing the allelic loss of autophagy 
genes such as beclin1 and ATG4 being associated with cancer development as well as 
other work showing a requirement for autophagy in the survival of cancer cells under 
metabolic stresses such as hypoxia (23, 24). In melanoma, a high autophagic index has 
been linked to chemotherapy resistance as well as constituting an important cell death 
mechanism (22, 25).  In the current study we investigated the mechanism underlying 
the clinical activity of the AKT inhibitor MK-2206 in combination with paclitaxel and 
carboplatin in BRAF WT melanoma patients [234]. A phase I dose-escalation trial was 
opened to investigate the utility of combining MK-2206 with carboplatin and paclitaxel 
(arm 1), docetaxel (arm 2), or erlotinib (arm 3) in patients with advanced solid tumors 
[234]. The combination of MK-2206 with carboplatin and paclitaxel (arm 1) resulted in 
the best anticancer activity among the different combinations tested, with a confirmed 
partial response and disease stabilization achieved in two BRAF wild type melanoma 
patients [234].  We present new data showing the importance of autophagy induction 
both for the cytotoxic activity of this drug combination as well as an important 
therapeutic escape mechanism. We suggest that the effectiveness and durability of the 
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MK-2206 combined with paclitaxel and carboplatin could be improved through the 
addition of autophagy inhibitors.  
 
RESULTS 
AKT inhibition enhances the efficacy of chemotherapy in melanoma patients 
 Two stage IV melanoma patients were enrolled at the Moffitt Cancer Center on 
the phase I clinical trial of escalating doses of MK-2206 in combination with carboplatin 
at an area under the curve (AUC) concentration of 6 and paclitaxel at 200mg/m2, both 
administered every 3 weeks [234].  Both individuals were confirmed to have BRAF WT 
melanoma by pyrosequencing: the NRAS status of the specimens was not available.  
Each of the patients received MK-2206 orally given prior to chemotherapy. Patient 1 
was a 66-year-old male with liver metastases, subcutaneous disease and hilar lymph 
node involvement and was treatment naïve prior to entering the trial. He received MK-
2206 at 90 mg every 3 weeks for 5 cycles and then went on to receive maintenance 
MK-2206 at 125 mg weekly. Restaging scans demonstrated a confirmed partial 
response with resolution of metastases in the right trapezius and liver observed (Figure 
6A). This response continued while on maintenance for approximately 16 months. The 
patient continued on therapy until restaging scans demonstrated progression of disease 
with a sub-cranial lymph node, mesenteric nodules, as well as a new right 
supraclavicular nodule. Patient 2 was a 68-year-old woman with a history of rheumatoid 
arthritis who presented with an intra-abdominal mass and hilar lymph node involvement, 
and was also treatment naïve before enrollment in the trial. She received MK-2206 135 
mg every 3 weeks for 4 cycles followed by maintenance MK-2206 at 135 mg weekly.  
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Figure 6. MK-2206 enhances the efficacy of carboplatin and paclitaxel in patients 
with BRAF-WT melanoma 
(A) Patients were treated with carboplatin, paclitaxel and MK-2206 in a phase I dose 
escalation study (NCT00848718). Patient 1 experienced a confirmed partial response. 
Upper 3 panels demonstrate resolution of a metastasis at the right trapezius. Lower 3 
panels demonstrate resolution of a liver metastasis in the liver lobe. This response 
continued while on maintenance MK-2206 for 16 months. (B) Patient 2 experienced 
stable disease, which continued for 12 months while on maintenance MK-2206.  
Demonstrate resolution of an intra-abdominal mass. (C) Immunohistochemistry 
conducted upon disease progression in the brain from patient 2 revealed PTEN (pink) 
status and high pAKT activity (brown).    
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This patient experienced disease stabilization for approximately 1 year (Figure 6B). This 
patient remained on therapy until restaging imaging demonstrated progression in the 
brain. IHC of the resulting melanoma brain metastasis 10 days after the cessation of 
MK-2206 therapy showed positive staining for PTEN and constitutive pAKT signaling 
(Figure 6C). The intra-abdominal mass subsequently increased in size significantly after 
discontinuing MK-2206 and became more symptomatic. The patient was then treated 
with radiation in this area and has not required further therapy since that time. Both 
patients were alive at the time of submission.   
 
MK-2206 inhibits AKT signaling in melanoma cell lines that are BRAF WT 
Western Blot studies showed the majority of BRAF/NRAS WT melanoma cell 
lines to have constitutive phosphorylation of AKT at Ser473 and Thr308 and to retain 
expression of the negative PI3K/AKT pathway regulator PTEN (Figure 7A). Two cell 
lines that were NRAS mutant and BRAF WT showed some constitutive activation of 
AKT, with one cell line (M318) lacking PTEN expression (Figure 7A). Treatment of a 
panel of 4 BRAF WT melanoma cell lines with MK-2206 inhibited constitutive AKT 
signaling as shown by the reduction in AKT phosphorylation at Ser473 (Figure 7A). 
Despite AKT being inhibited by MK-2206, little effect was seen upon the growth, 
apoptosis and survival of BRAF WT melanoma cell lines under both 2D and 3D cell 
culture conditions until concentrations >1 µM (Figure 7B,C).  In colony formation assays 
MK-2206 had modest effects upon the long-tem survival of 6 BRAF WT cell lines 
(Figure 7D). 
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Figure 7. The AKT inhibitor MK-2206 suppressed the growth of BRAF-WT 
melanoma cells, but did not induce cytotoxicity. 
(A) (Upper) Western Blot showing basal PTEN and pAKT (S473, T308), pGSK-3α 
(Ser21) expression in BRAF/NRAS-WT and NRAS mutant cell lines. (Lower) Cells were 
treated with increasing concentrations of MK-2206 for 24 hours and immunoblotted for 
expression of pAKT (pAKT) (S473) and total-AKT. (B) Cells were treated for 72 hours, 
and cell numbers were quantified using Alamar blue assay. (C) Preformed spheroids 
were treated with MK-2206 (5 µM for 72 hours) before being treated with calcein-AM 
and Ethidium bromide. Green, viable cells; red, dead cells. Magnification x 10. (D) 
(Upper) A panel of BRAF/NRAS-WT melanoma cell lines were treated with vehicle or 
MK-2206 (5µM) for 4 weeks. After this time, colonies were fixed and stained with crystal 
violet. Photographs are representative of three independent experiments. (Lower) A 
panel of BRAF/NRAS WT melanoma cell lines were treated with MK-2206 (5µM) for 72 
hours before being stained with annexin-V and analyzed by flow cytometry. 
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Acute treatment with MK-2206 does not significantly enhance carboplatin/paclitaxel-
induced apoptosis  
Since clinical responses were observed to the combination of MK-2206 with 
cytotoxic chemotherapy, we next asked whether combination with paclitaxel and 
carboplatin enhanced the cell death response in vitro. A panel of melanoma cell lines 
was treated for 72 hours with MK-2206, carboplatin plus paclitaxel, or the combination 
of all three agents. Although it was noted that treatment of WM209, M257, M285, M368 
and WM3918 melanoma cells with the combination was associated with a significant 
enhancement in the inhibition of proliferation in an Alamar assay, these effects were 
less than additive (Figure 8A). Little increase in apoptotic cell death was seen from the 
concurrent combination of MK-2206 + chemotherapy following 72 hours treatment 
(Figure 8B).  
 
Induction of cell death following chronic treatment with MK-2206 in combination with 
carboplatin and paclitaxel 
  Instead, more dramatic effects were seen in longer-term experiments with the 
combination of MK-2206 and chemotherapy found to almost completely prevent the 
formation of colonies, compared to either MK-2206 or chemotherapy alone (Figure 9A).  
Significant cytoxicity was achieved in 3D collagen implanted spheroid assays treated for 
216 hours, where MK-2206 plus carboplatin and paclitaxel combination correlated with 
a marked reduction in cell viability (Figure 9B), leaving only a few viable cells.  
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Figure 8. The AKT inhibitor MK-2206 does not enhance the cytotoxic effects of 
carboplatin and paclitaxel after acute drug exposure.  
(A) Melanoma cells were either treated with vehicle, MK-2206 (5 µM), carboplatin (1 
µM), paclitaxel (3 nM) or the combination of all three agents for 72 hours, and cell 
numbers were quantified using Alamar blue assay. (B) Melanoma cells were either 
treated with vehicle, MK-2206, carboplatin, paclitaxel or the combination of all three 
agents for 72 hours, and apoptosis levels were assessed by annexin-V staining and 
flow cytometry.  
 
 
 
Similar results were observed by flow cytometry where cells treated with the 
combination of MK-2206 and carboplatin plus paclitaxel beyond 72 hours exhibited 
significant apoptotic inductions, relative to treatment with MK-2206 or 
carboplatin/paclitaxel alone (Figure 9C). The normal human fibroblast cell line FF2507 
was not sensitive to the cytotoxic effects of MK-2206 plus carboplatin/paclitaxel 
treatment. 
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Figure 9. Chronic treatment with MK-2206 in combination with paclitaxel and 
carboplatin induces significant cell death. (A) A panel of BRAF/NRAS-WT 
melanoma cell lines was treated with vehicle, MK-2206, carboplatin, paclitaxel or the 
combination of all three agents for 4 weeks. After this time, colonies were fixed and 
stained with crystal violet. (B) Spheroids were treated with MK-2206, carboplatin and 
paclitaxel, or the combination of all three agents (for 72, 144 or 216 hours) before being 
treated with calcein-AM and Ethidium bromide. Lack of green staining also indicates a 
loss of cell viability. Magnification x 10. (C) M368, WM3918, M257 and FF2507 (normal 
stromal fibroblasts) cells were treated up to 216 hours with vehicle, MK-2206, 
carboplatin, paclitaxel or the combination of all three agents. Apoptosis was 
subsequently assessed after annexin-V binding via flow cytometry. 
 
 
AKT inhibition enhances chemotherapy-induced autophagosomal formation 
The combination of MK-2206 with chemotherapy was shown to have a significant 
cytostatic effect within 72 hours of treatment, however unable to induce appreciable 
levels of apoptosis compared to those achievable from chemotherapy alone, until 
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treatment was extended beyond 72 hours. We next sought out to understand what 
mechanism(s) was responsible for the impressive temporal switch in sensitivity 
occurring within our experimental system. A recent study where MK-2206 was 
combined with gefitinib in glioma reported an induction of cytoprotective autophagy 
blunted the efficacy of their treatment regimen [289]. A few other groups reported similar 
phenomena where protective autophagy induced in response to AKT inhibition from 
MK-2206 weakened the efficacy of treatment [290, 291]. As the PI3K/AKT/mTORC1 is 
one major regulator of autophagy, inhibition of AKT leading to an induction of autophagy 
fits with what is understood in the literature, as this would lead to a loss of activity in 
mTORC1, relieving ULK1 of the inhibitory control of mTORC1, and allowing an 
induction of autophagy to occur [255, 292]. The identification of autophagosomes 
through transmission electron microscopy is the method by which autophagosomes 
were discovered [251], and remains a critical assay to utilize in studies of autophagy 
[246]. It was noted that whereas treatment with carboplatin/paclitaxel alone, and single 
agent MK-2206 increased the numbers of autophagosomes compared to the vehicle 
control, the largest number of autophagosomes were seen in cells treated concurrently 
with MK-2206 and chemotherapy (Figure 10A). In a similar vein, the AKT inhibitor plus 
chemotherapy combination also increased the accumulation of LC3 punctae, compared 
to either MK-2206 or chemotherapy alone (Figures 10B). LC3 represents the best 
protein marker for autophagosomes, and becomes lipidated when bound to 
autophagosomal membranes, compared to its non-lipidated cytosolic state [246]. The 
association to autophagosomes makes LC3 appear as punctae when imaged by 
immunofluorescent microscopy [246]. By Western blot analysis, lipidated LC3 
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associated to autophagosomes appears as a lower migrating form (Figure 10C). 
Treatment of a panel of BRAF/NRAS wild type melanoma cells reveals chemotherapy 
and MK-2206 each can induce autophagosomal accumulation as single agents, 
however the greatest increase in LC3 II levels occurs from the concurrent treatment of 
MK-2206 and chemotherapy across the majority of the cell line panel (Figure 10C). 
Calculation of the LC3II/I ratio was based on densitometry analysis of both bands, a 
standard method to assess autophagosome levels [246]. 
 
The combination of MK-2206 with chemotherapy induces greater autophagic flux than 
each of the agents alone 
 The addition of MK-2206 to carboplatin and paclitaxel was observed to increase 
the number of autophagosomes within the cell, as observed by TEM and LC3, however 
this does not necessarily prove that an induction of autophagy from our treatment 
combination has occurred. Autophagosomes can accumulate within a cell for a number 
of reasons, and can reflect reduction in autophagosomes turnover [248, 249], inefficient 
fusion between autophagosomes and lysosomes [250], or disruption in lysosome 
functionality rather than an induction to autophagy [246]. For example, treatment of 
WM3918 cells with the autophagy inducer rapamycin causes an increase in LC3 II, as 
does treatment with the autophagy inhibitor chloroquine (Figure 11A), highlighting the 
caveat of using LC3 alone as an indicator of autophagy activity. 
One technique that differentiates between an induction of autophagy versus a 
block in functional autophagy is the bafilomycin clamp [260, 293].  
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Figure 10. Combining the AKT inhibitor MK-2206 with carboplatin and paclitaxel 
leads to an increase in autophagosomes.  
(A) M368 cells were treated with MK-2206, Carboplatin and Paclitaxel or the 
combination of all three agents for 72 hours. Cells were subsequently processed for 
TEM. Shown are representative images. Scale bar: 2µm. (B) Immunofluorescence 
staining of LC3A (green) and DAPI (blue) in M368 cells following treatment with labeled 
agents for 72 hours. (C) Western blot studies of treated BRAF/NRAS-WT melanoma 
cell lines as labeled for 72 hours for LC3A. 
 
 
To determine whether the increase in LC3 II induced from the concurrent treatment of 
chemotherapy and MK-2206 is indicative of an increase in autophagic flux or block in 
autophagosomal degradation, LC3 II turnover must be compared in the presence and 
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absence of saturating levels of bafilomycin [246, 274]. Treatment of the cells with 
bafilomycin further increased the accumulation of LC3 II in the presence of the 
chemotherapy/MK-2206 combination, indicating an increase in autophagic flux. (Figure 
11A, B). It was also shown that concurrent treatment with MK-2206 and chemotherapy 
yielded a greater increase in autophagic flux, relative to what was achieved from single 
agent MK-2206 or chemotherapy (Figure 11C). As the late stages of autophagy involve 
increased lysosome formation, we next stained drug-treated cells with acridine orange, 
a dye that changes its fluorescent properties from green to orange upon protonation in 
acidic intracellular compartments [246, 274].  It was observed that treatment with MK-
2206 or chemotherapy alone only induced limited protonation of acridine orange, 
however intense staining for protonated acridine orange was observed when BRAF WT 
cells were treated with the combination of MK-2206 + chemotherapy (Figure 11D).  
 
Autophagy initially protects from MK-2206+chemotherapy mediated cell death 
 Autophagy has been paradoxically linked to both cell death and the promotion of 
survival [237, 269]. We next determined the functional role of autophagy induction and 
whether this preceded the later cell death response. In WM209, M285, M368 and 
WM3918 BRAF WT melanoma cell lines it was noted that autophagy induction, as 
shown by accumulation of LC3-II was relatively rapid, compared to the much slower 
induction of apoptosis, as demonstrated by increased detection of cleaved caspase-9 
and annexin-V binding (Figure 12A, 9C).  
  We next demonstrated that the cytotoxic activity of AKT inhibition + 
chemotherapy was dependent upon caspase-mediated cell death with pre-treatment  
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Figure 11: Concurrent treatment with MK-2206 plus chemotherapy induced the 
greatest increase in autophagic flux. (A) (Left) WM3918 cells were treated with 
rapamycin, chloroquine, or MK-2206 plus carboplatin/paclitaxel (24 hours) in the 
presence or absence of bafilomycin (1 nM, 1 hour). Western blotting was performed 
from collected lysate for LC3. (Right) Ratio of LC3 II/I ratios was calculated by 
densitometry analysis for bafilomycin vs. control co-treatment. Ratios higher than 1 
(dashed line) indicate an autophagy inducer or control; ratios lower than 1 indicate an 
autophagy inhibitor [274]. (B) WM209, M257, M285, M368 and WM3918 cells were 
treated with MK-2006 plus carboplatin/paclitaxel (24 hours) in the presence or absence 
of bafilomycin (1 nM, 1 hour). Western blotting was subsequently performed for LC3A 
protein levels. (C) WM3918 cells were treated with bafilomycin (1 nM), 
carboplatin/paclitaxel, MK-2206 or the combination of MK-2006 plus 
carboplatin/paclitaxel in the presence of bafilomycin. Western blotting was performed for 
LC3A protein levels. (D) Fluorescence imaging of WM209, M368 and WM3918 cells 
treated as indicated for 72 hours and stained with AO. Red indicates intracellular acidity, 
associated with increased auto-lysosomal activity. 
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with the pan-caspase inhibitor z-vad-fmk found to partly reverse MK-
2206/carboplatin/paclitaxel-mediated cytotoxicity in a 3D spheroid assay (Figure 12B). 
Addition of the autophagy inhibitor chloroquine significantly enhanced the anti-
proliferative effects seen to the combination of MK-2206 and chemotherapy, and also 
increased the levels of apoptosis (Figure 12C). Similar results were observed with 
bafilomycin (data not shown). It was further noted that the addition of chloroquine 
enhanced the cell death response to MK-2206 + chemotherapy after 3 days in the 
spheroid assay (Figure 12D). Taken together these results suggested that the induction 
of autophagy was serving a cyto-protective role from the short-term effects of MK-2206 
and chemotherapy.  
 
Depletion of ATG5 prevents autophagy induction and limits escape from the 
combination of MK-2206 + chemotherapy 
We demonstrate autophagy serves a cyto-protective resistance mechanism, 
allowing escape from acute concurrent MK-2206 plus carboplatin and paclitaxel 
treatment. However, the role autophagy plays in the long-term activity reported in the 
two melanoma patients (Figure 6A,B) and in our long-term experiments (Figure 9A,B,C) 
is unclear. We next explored the role of autophagy induction in the long-term responses 
to the combination of MK-2206 + chemotherapy using a genetic model where 
autophagy was abrogated through the silencing of ATG5, a protein required for the 
maturation of autophagosomes (Figure 13A). In mouse embryonic fibroblasts (MEFs) 
null for ATG5 (-/-), the AKT inhibitor + chemotherapy combination was unable to induce  
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Figure 12. Induction of autophagy is initially cyto-protective. 
(A) Western blot showing time-dependent accumulation of LC3 II and caspase 9 
cleavage following treatment with the combination of MK-2206, paclitaxel and 
carboplatin. (B) 3D collagen-implanted spheroids were treated with carboplatin and 
paclitaxel, MK-2206, MK-2206/carboplatin/paclitaxel, or the combination of MK-
2206/carboplatin/paclitaxel with the caspase inhibitor z-Vad (50µM) over the course of 
144 hours. Spheroids were subsequently imaged with immunofluorescent microscopy 
following treatment with calcein-AM and Ethidium bromide. (C) (Upper) A panel of 
BRAF/NRAS wild type cell lines were treated with either chloroquine (12.5-50µM), MK-
2206/carboplatin/paclitaxel or the combination of all agents for 72 hours. Cell numbers 
were quantified using Alamar blue assay. (Lower) Melanoma cells were treated with 
chloroquine alone (50µM), MK-2206/Carboplatin/Paclitaxel, or the combination of all 
four agents for 72 hours. Apoptosis was subsequently assessed by annexin-V staining 
and flow cytometry. (D) 3D collagen-implanted spheroids were treated with vehicle, MK-
2206/Carboplatin/Paclitaxel, in the absence and presence of chloroquine (50µM) for 72 
hours, before being treated with calcein-AM and Ethidium bromide.  
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autophagy, as demonstrated by the lack of LC3-II induction by Western blot and the 
absence of LC3 punctae (Figure 13B,C). In contrast, treatment of isogenic ATG5+/+ 
MEFs with this drug combination led to the strong induction of LC3-II and the formation 
of punctae (Figure 13B, C). In short-term assays, no induction of PARP cleavage was 
noted in either the ATG5+/+ or ATG5-/- cells (Figure 13B). It was further observed that the 
ATG5-/- cells exhibited more cell death following treatment with the drug combination 
than the ATG5+/+ MEFs in 3D spheroid assays (Figure 13D). In 4 week colony formation 
assays, clones were observed in the ATG5+/+, but not the ATG5-/- MEFs following MK-
2206 + chemotherapy treatment, suggesting a requirement for autophagy induction in 
the eventual escape from therapy (Figure 13D).  
 
MK-2206 plus chemotherapy induces ROS-mediated cytotoxicity in BRAF WT 
melanoma cells 
 The blockade of lysosomal function in cells reliant upon autophagy is known to 
increase the levels of reactive oxygen species (ROS) [231].  Pre-treatment of cells with 
the ROS detector dihydrorhodamine-123 showed the combination of MK-2206 + 
chemotherapy to increase intracellular levels of ROS compared to either AKT inhibitor 
or chemotherapy alone (Figure 14A). Even greater increases in intracellular ROS levels 
were seen when cells were treated with CQ (Figure 14A), an effect that was further 
enhanced following treatment with the combination of CQ, MK-2206 and chemotherapy 
(Figure 14A). The importance of ROS generation in the pro-apoptotic effects of the MK-
2206 plus carboplatin and paclitaxel combination, in the absence or presence of an  
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Figure 13. Long-term autophagy induction is required for the escape from MK-
2206/paclitaxel/carboplatin treatment. 
(A) Western blot showing lack of ATG5 expression and LC3 II in MEFs that are ATG5-/-. 
(B) MK-2206 based drug combinations induce LC3 II expression in ATGF5+/+ but not 
ATG5-/- MEFs. (C) IF microscopy with IF-LC3 antibody of ATG5 isogenic pair of cell 
lines treated for 72 hours with labeled agents. Deletion of ATG5 abrogates therapeutic 
escape. (D) Long-term colony formation assays with ATG5-/- and ATG5+/+ MEFs 
following labeled treatment. Preformed ATG5+/+ and ATG5-/- MEF spheroids were 
treated with carboplatin/paclitaxel, MK-2206 or carboplatin/paclitaxel/MK-2206 for 72 
hours before being stained with calcein-AM and Ethidium bromide. 
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autophagy inhibitor, was demonstrated by the rescue observed following pre-treatment 
with the anti-oxidants Tiron and n-acetyl cysteine (NAC) (Figures 14B). Treatment with 
Tiron also reversed cytotoxicity to the MK-2206, CQ and chemotherapy combination in 
3D spheroid assays (Figure 14C). Similar results were obtained in spheroids treated 
with NAC (data no shown). Long-term treatment regimens revealed that ROS levels 
were significantly increased after 144 and 216 hours of concurrent treatment with 
chemotherapy and MK-2206, compared to cells that were only treated with either 
chemotherapy or MK-2206 alone (Figure 14D, E). The greatest increases in ROS levels 
correlated with the same time points where the chemotherapy and MK-2206 
combination induced the highest apoptosis (Figure 14E, 9A, C). This observation, 
together with the rescue from apoptosis conferred by treatment with the ROS 
scavengers NAC and Tiron, suggest the mechanism behind the long-term efficacy of 
chemotherapy plus MK-2206 is ROS-mediated. Further, MK-2206 plus chemotherapy 
treatment-induced autophagy appears to protect the cells by transiently shielding the 
cells from ROS-induced cytotoxicity. 
 
Discussion 
Melanoma continues to be the poster child for targeted therapy development in 
cancer with the MAPK signaling pathway representing a uniquely successful target for 
this disease [286, 288, 294]. Despite most melanomas showing some level of 
constitutive activity in the MAPK signaling pathway, other signal transduction cascades 
including the PI3K/AKT pathway are also important for melanoma development [228, 
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233, 295]. In melanoma, PI3K/AKT signaling can be driven through loss of PTEN, 
increased  
                   
Figure 14. Autophagy prevents ROS-mediated cytotoxicity in BRAF wild type 
melanoma cells treated with MK-2206 + chemotherapy. 
(A) WM3918 cells were treated with either MK-2206, chloroquine (50µM), carboplatin 
and paclitaxel, or the combination of all agents over the course of 72h. H2O2 (250µM, 
10 minutes) was used as a positive control for reactive oxygen species detection. All 
cells were subsequently stained with DHR-123 (10µM, 10 minutes) and fluorescence 
was measured using flow cytometry. (B) WM3918 cells were treated with Tiron (2µM), 
NAC (5µM), carboplatin, paclitaxel, MK-2206 and/or chloroquine (50µM) as labeled on 
the graph for 72 hours. Apoptosis was assessed by annexin-V staining and flow 
cytometry. (C) Spheroids were treated with Tiron (2µM), carboplatin, paclitaxel, MK-
2206 and/or chloroquine (50µM) as labeled, before being treated with calcein-AM and 
Ethidium bromide. (D) WM3918 and M368 were treated with MK-2206, carboplatin and 
paclitaxel or the combination of all agents over the course of 216 hours. All cells were 
subsequently stained with DHR-123 (10µM, 10 min) and fluorescence was measured 
using flow cytometry. (E) Increased ROS detection in cells treated with MK-2206, 
carboplatin and paclitaxel or the combination of all agents over the course of 216 hours 
	   70 
was standardized compared to control levels. Data represents the mean of 3 
independent experiments. 
 
 
expression of AKT3, NF1 loss, mutations in NRAS, and rarely through AKT and PI3K 
mutations. Activity in this pathway plays a key role in melanoma development by 
allowing BRAF-transformed melanocytes to bypass oncogene-induced senescence [82, 
226, 228, 229, 296, 297]. Once melanoma is initiated, AKT signaling plays a role in 
tumor progression through effects upon survival [232, 298]. Recent work from our lab 
has further shown a role for adaptive PI3K/AKT signaling in the escape of BRAF mutant 
melanoma cells from the pro-apoptotic effects of BRAF inhibition [95]. Despite these 
data, the potential utility of targeting AKT in BRAF/NRAS WT melanoma has been little 
explored.  
An initial analysis of AKT signaling in a panel of seven BRAF/NRAS WT 
melanoma cell lines showed the majority to have constitutive AKT phosphorylation at 
both Ser473 and Thr308, indicative of baseline signaling in the pathway. Despite AKT 
being implicated in cell survival through the direct regulation of BAD phosphorylation at 
Ser99, single-agent MK-2206 treatment had relatively minor effects upon melanoma cell 
growth and induced little cell death under either 2D or 3D cell culture conditions [299]. 
Our results mirror previous studies on NRAS mutant melanoma, showing that shRNA 
knockdown and pharmacological inhibition of PI3K to be ineffective as a single agent, 
with concurrent BRAF or MEK1/2 inhibition being required for significant anti-tumor 
activity [300, 301].  The reason for the apparent lack of single agent activity to MK-2206 
likely results from the high levels of signaling redundancy in melanoma cells. It is 
already known from extensive studies in cell lines harboring BRAF mutations that 
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melanoma survival is highly dependent upon the MAPK pathway, which exerts its 
effects in part through regulation of the pro-apoptotic proteins BIM and BMF [302, 303].  
Given that the survival of melanoma cells is regulated through the balanced expression 
of both pro and anti-apoptotic BH3 family proteins, it seems likely that AKT inhibition 
alone is not sufficient to alter the life/death equilibrium and push the cells into apoptosis. 
Although AKT inhibitors lack significant single-agent activity, they are known to 
synergize with many other agents including chemotherapy drugs (camptothecin, 
docetaxel, doxorubicin, 5-FU, carboplatin and targeted therapy agents (erlotinib and 
gefitinib) [289, 304]. In BRAF WT melanoma cell lines, the combination of MK-2206 with 
paclitaxel and carboplatin did not substantially enhance either growth inhibition or 
apoptosis induction at time points up to 72 hours.  As these modest effects were not in 
agreement with the observed prolonged anti-tumor activity of the MK-
2206/paclitaxel/carboplatin combination seen in melanoma patients, we next undertook 
longer-term treatments in which the cultures were grown in drug for extended periods of 
time (up to 4 weeks), using a schedule analogous to that used in the phase I clinical trial 
(an initial dose of chemotherapy followed by continual MK-2206 treatment). Under these 
conditions, profound levels of growth inhibition were observed, suggesting that the AKT 
inhibitor/chemotherapy combination had effects beyond the short-term induction of 
apoptosis and growth inhibition.   
One of the major targets of AKT is the mammalian target of rapamycin (mTOR), 
a serine/threonine kinase that plays a key role in the regulation of cell growth through its 
activity as a sensor of amino acid and ATP levels [255]. Inhibition of the 
PI3K/AKT/mTOR signaling pathway mimics nutrient starvation and leads to the 
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induction of autophagy [292, 305].  From a signaling standpoint the ULK1 (ATG1) 
kinase complex is critical in integrating metabolic stress signals from the mTOR 
signaling pathway. Following the inhibition of mTORC1, the cytoplasmic autophagy 
machinery is recruited onto phospholipid membranes derived from the endoplasmic 
reticulum (ER) and the golgi apparatus leading to the formation of autophagosomes, 
which then mature with the aid of ATG5 and LC3 [306].  As the final step, the 
autophagosomes are delivered to the lysosomes, the contents broken down by 
lysosomal hydrolases and the degradation products recycled back to the cytosol [306].   
Many anti-cancer drugs, including the AKT inhibitor MK-2206 and 
chemotherapeutic agents such as cisplatin, 5-fluorouracil and paclitaxel are known 
inducers of autophagy [272, 289, 307].  Treatment of BRAF WT melanoma cells with 
MK-2206 induced autophagy as shown by an increased accumulation of the lipidated 
form of LC3 (LC3-II), enhanced autophagic flux (increased staining for the protonated 
form of acridine orange, increased LC3-II accumulation in the presence of bafilomycin) 
and the formation of autophagosomes as detected by electron microscopy. The addition 
of paclitaxel and carboplatin to MK-2206 markedly enhanced autophagic flux compared 
to what was achievable by any of the agents alone, and at later time points increased 
the extent of cell death. In cancer, autophagy is most often associated with increased 
cell survival, particularly under conditions of stress such as hypoxia, nutrient deprivation 
and drug therapy [240, 277]. Melanoma is a tumor with high basal levels of autophagy 
(typically 20-27% of specimens show evidence of LC3 punctae), and this has been 
linked to both chemoresistance and increased tumor aggressiveness [266, 270].  
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Autophagy also plays a role in therapeutic escape in cancer by allowing 
malignant cells to remain dormant but yet viable in the presence of drug as well as 
facilitating the evasion from alkylating agents by limiting the DNA damage response 
[308].  In BRAF WT melanoma cells, autophagy induction at the earlier time points of 
drug treatment was associated with therapy resistance, with enhanced cell death 
responses in 3D culture and increased levels of apoptosis observed following the 
addition of the autophagy inhibitors chloroquine and bafilomycin. Treatment of isogenic 
pairs of MEFs that either expressed ATG5 or had ATG5 deleted (+/+ or -/-) also 
revealed a role for autophagy in resistance to the MK-2206+paclitaxel/carboplatin 
combination, with no ATG5-/- MEF colonies remaining after 4 weeks of drug treatment. 
Knockdown or deletion of ATG5 prevents the autophagy process from being completed 
by blocking autophagosome maturation [243]. In all cases, inhibition of autophagy was 
associated with an increased accumulation of ROS. A link between ROS generation 
and eventual cell death was demonstrated by the ability of the anti-oxidants Tiron and 
NAC to abrogate the extent of cell death induced by the MK-2206/paclitaxel/carboplatin 
combination in the presence or absence of chloroquine (Figure 15). Our observations 
agree with previous studies showing that autophagy induces mitochondrial ROS and 
that these effects are enhanced following chloroquine treatment [231]. In this context 
the impaired autophagosome production following chloroquine treatment contributes to 
ROS-mediated damage through the accumulation of deleterious oxidative products 
such as lipofuscin/ceroid [231].    
Despite being mostly linked to cells survival, persistent, high-level induction of 
autophagy can also be deleterious [289, 309].  Treatment of BRAF WT melanoma cells 
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with MK-2206+chemotherapy for extended periods of time (6 and 9 days) induced high 
autophagy levels and an eventual switch to caspase-mediated apoptotic cell death, as 
shown by increased caspase 9 cleavage and the ability of the caspase inhibitor z-vad-
fmk to reverse the cytotoxic effects of the drug combination.  The switch from protective 
autophagy to eventual cell death upon prolonged drug treatment has been reported in 
other tumor systems. In glioma, the combination of MK-2206 + the EGFR inhibitor 
gefitinib has been shown to be initially protective and sensitive to increased 
chloroquine-mediated cytotoxicity before eventual entry into apoptotic cell death [289]. 
In melanoma, a similar switch to autophagy-mediated cell death has been reported 
following treatment with polyinosine-polycytidylic acid [309]. As such, the inhibition of 
autophagy, using the lysomotropic agents chloroquine and hydroxychloroquine, are 
currently being explored clinically in combination with other anti-cancer agents across 
multiple solid tumor types [274, 282]. There is already some suggestion of clinical 
benefit to inhibiting autophagy, with a phase III clinical trial of glioblastoma patients 
showing an increased response rate when hydroxychloroquine was added to 
carmustine and radiation [271]. In another clinical trial, the combination of 
hydroxychloroquine and the mTOR inhibitor temsirolimus was associated with stable 
disease in 10/14 (including 4/5 patients with melanoma) patients [310].  In summary, we 
have shown for the first time the potential efficacy of AKT inhibition in combination with 
chemotherapy in BRAF WT melanoma. Through mechanistic studies, we have 
demonstrated this combination to induce high, sustained levels of autophagy leading to 
eventual caspase-mediated cell death. Induction of autophagy was found to be critical in 
allowing minor populations of cells to escape from this regimen, and we suggest that the 
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timed addition of an autophagy inhibitor may be one strategy of limiting the onset of 
resistance. 
 
 
Figure 15: Overall scheme depicting the mechanisms underlying the activity of 
MK-2206 plus carboplatin and paclitaxel. Treatment with chemotherapy alone 
displayed modest effects upon proliferation, apoptosis and colony formation. However, 
a large amount of resistant clones persisted and were associated with an increase in 
AKT activity. The addition of MK-2206 to chemotherapy resulted in enhanced inhibition 
of proliferation however no significant contribution to chemo-induced apoptosis was 
observed in 72 hours of treatment. This was correlated with an increase in autophagic 
flux, which played a cyto-protective role. The inhibition of autophagy conferred 
sensitivity to the MK-2206 plus carboplatin and paclitaxel combination, and also yielded 
a significant increase in ROS levels. Treatment-induced ROS was shown to be 
functional in the cytotoxicity observed from MK-2206 plus carboplatin and paclitaxel 
treatment, both in the presence and absence of autophagy inhibitors. Autophagy 
appears unable to protect the cells beyond 72 hours of MK-2206 plus carboplatin and 
paclitaxel treatment from the cytotoxic effects of ROS. 
 
	   76 
Materials and Methods 
Cell culture and proliferation assay 
 The melanoma cell lines WM3918, WM209 and WM1963 were a gift from Dr. 
Meenhard Herlyn (The Wistar Institute, Philadelphia, PA) and were grown in RPMI 
supplemented with 5% fetal bovine serum. The melanoma cell lines M257, M285 and 
M368 were a kind gift from Dr. Antoni Ribas (The Jonsson Comprehensive Cancer 
Center, Los Angeles, CA). ATG5-/- and ATG5+/+ mouse embryonic fibroblasts were a 
kind gift from Dr. Shengkan Jin (Rutgers University, Piscataway, NJ). MTT assays were 
performed as follows. Cells were plated 2,000 per well in a 96-well cell culture plate and 
allowed to adhere over night. After 24 h, cells were treated with various combinations of 
5uM MK-2206, 1uM Carboplatin, 3nM Paclitaxel, 12.5-50uM Chloroquine, and/or 1nM 
Bafilomycin over the course of 72 h. After treatment, proliferation was quantified by 
using Alamar Blue from Life Technologies according to the manufacturers instruction 
and absorbance of the stain was read using a plate reader.   
 
Western blotting 
 Cells were plated 500,000 per 10 cm cull culture petri dish and allowed to adhere 
over night. The next day, cells were treated with various combinations of 5uM MK-2206, 
1uM Carboplatin and 3nM Paclitaxel (24-72 h); cells were subsequently harvested from 
cell culture plates using 0.25% trypsin and protein lysate was purified using a RIPA 
digest. Lysate was then loaded into 10, 12 or 15 well gels and then transferred unto 
membranes. Membranes were activated in methanol, allowed to dry for 15 minutes and 
then blocked for one hour in a solution of 5% dried non-fat milk in TBST. After blocking, 
	   77 
membranes were briefly washed in TBST, primary antibodies were suspended in a 
1:1000 dilution in either 5% dried non-fat milk in TBST or 5% BSA in TBST according to 
the manufacturers instructions. Primary antibodies were allowed to incubate over night 
at 4°C. The next day, membranes were washed for 15 minutes three times with TBST. 
Mouse or rabbit secondary antibody was suspended in a 1:2000 dilution in 5% dried 
non-fat milk in TBST according to the species of primary antibody used. Membranes 
were incubated in secondary antibody for an hour on a shaker at room temperature and 
subsequently washed with TBST for 20 minutes three times. Membranes were than 
developed using ECL and film. The antibodies to phospho-AKT (Ser473 and Thr308), 
total AKT, PTEN, GSK-3α, pGSK-3α (Ser21) cleaved-Parp, cleaved caspase 9, ATG5 
and LC3A were from Cell Signaling Technology. 
 
Flow cytometry and Reactive Oxygen Species Detection 
 Cells were plated 150,000 per well in a 6-well cell culture plate and allowed to 
adhere overnight. The next day cells were treated with 3nM paclitaxel, 1uM carboplatin, 
5uM MK-2206, 50uM chloroquine and/or 3nM bafilomycin and harvested after 72 hours 
using 0.25% trypsin. Cells were pelleted with a centrifuge, supernatant was aspirated 
and cells were pashed with 1mL of annexin V binding buffer. Cells were pelleted once 
more, supernatant aspirated, resuspended in 50uL of annexin-V binding buffer and 
transferred to facs tubes. Cells were stained with Annexin-V and TMRM for 15 minutes 
at 37°C and then passed through a cell strainer to attain a single cell suspension for 
analysis by LSR-II flow cytometer.  
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Reactive oxygen species levels were detected in cells treated for 72 hours with 
paclitaxel, carboplatin, MK-2206 and or chloroquine. Cells were subsequently stained 
with dihydro-rhodamine 123 (10uM) for 10 minutes and fluorescence intensity was 
analyzed by flow cytometry. 
 
Immunofluorescence staining 
 Cover slips were sterilized with 70% ethanol, allowed to dry and placed onto the 
bottom of 6-well cell culture plates. 150,000 cells per well were plated onto the 
coverslips and allowed to adhere over night. The next day cells were treated with 
paclitaxel, carboplatin and/or MK-2206 for 72 hours before being fixed and 
permeabilized with methanol. Cells were than blocked with 1% BSA in TBST for 1 hour 
and then incubated in primary antibody over night at 4°C. The next day, cells were 
washed for 10 minutes three times with TBST and incubated in secondary IF antibody 
for 1 hour. Cells were finally washed in TBST for 15 minutes three times and imaged 
with a Leica confocal at 40X magnification. 
 
3D spheroid assays 
 Collagen implanted spheroids were prepared using the liquid overlay method and 
were treated with carboplatin, paclitaxel, MK-2206, chloroquine or all drugs in 
combination for 3, 6 and 9 days before being analyzed by fluorescence microscopy as 
described in ref. (11).   
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Transmission Electron Microscopy 
 Human melanoma cells were fixed with 2% gluteraldehyde and stored at 4°C 
until embedding. Cells were next fixed with 2% osmium tetroxide, followed by 
dehydration step composed of a series of increasing ethanol dilutions and propylene 
oxide. Cells were subsequently embedded in resin and sections were cut ultra thin 
(90nM), placed on uncoated copper grids, and stained with 0.2% lead citrate and 1% 
uranyl acetate. Images were taken with a JEOL 1400 transmission electron microscope 
at 80kV. 
 
Statistical analysis 
 Data show the mean of at least 3 independent experiments. GraphPad Prism 5 
statistical software was used to perform the Student’s t test where (*) indicates P≤0.05, 
(**) indicates 0.05 ≤	  P ≤	  0.01, (***) indicates P≤0.001 and (****) indicates P≤0.0001. 
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Chapter 3 
 Receptor Tyrosine Kinase Signaling Mediates Resistance in NRAS Mutant 
Melanoma 
 
Introduction 
Metastatic melanomas are known to exhibit aggressive clinical behavior and 
resistance to conventional and targeted therapies, making effective disease 
management difficult [277]. Key mutations in the MAPK pathway have been identified in 
the past decade and high pERK activity has been observed in as high as 90% of all 
melanomas, demonstrating the necessity of this pathway for the oncogenic phenotype 
in the majority of melanomas [153]. The ever-increasing response rates and clinical 
successes achieved in BRAF mutant melanomas is a testament to the strength behind 
genetic testing of patients for well characterized driver mutations as a tool to stratify 
patients upfront into different treatment strategies [3, 88, 100, 286]. Beyond BRAF 
inhibitors, there has also been much success with the utilization of the immunotherapy 
ipilimumab, with a subset of patients experiencing promising extensions in overall 
survival [31, 32]. However, responders to these agents cannot be identified prior to 
treatment by any genetic tests or molecular indicators, highlighting the difficulty in 
implementing such therapies to patients as first line treatment [30]. Further, there has 
been an unfortunate deficiency in effective targeted therapeutics for those melanomas 
that are BRAF wild type, comprising 50% of all melanomas, or roughly 38,000 
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melanoma patients yearly [33]. The best-characterized and most studied genetic 
subgroup is the 15-20% of melanomas with NRAS mutations [123]. NRAS mutant 
tumors also have constitutive activity of the MAPK pathway like their BRAF mutant 
cousins, however similar targeted regimens used to treat BRAF mutant melanomas 
have not been as feasible when translated to NRAS mutant melanomas. As discussed 
earlier, the use of BRAF inhibitors in cells with wild type BRAF yields excessive toxicity 
due to a drug-induced paradoxical activation of CRAF, and downstream MAPK pathway 
activity [160, 287]. Research has now focused upon targeting downstream of RAS/RAF 
with the development of potent inhibitors to MEK and ERK [162]. Of these, the use of 
the MEK inhibitor MEK162 in a phase II clinical trial achieved a historical bench mark in 
NRAS mutant melanoma, being the first targeted agent to have clinical efficacy [146]. 
The MEK inhibitor trametinib has also been effective, both preclinically and clinically, in 
melanoma and was recently FDA approved in 2013 [3]. Although targeting MEK has 
had some success in NRAS mutated melanoma, the evolving lesson from the use of 
small molecule BRAF inhibitors in patients with BRAF mutated melanoma suggests that 
resistance will always limit the response to single agent therapy and multiple drug 
combinations will be critical in preventing the onset of resistance. In the current study, 
we investigated the mechanism underlying NRAS mutant melanoma cell resistance to 
MEK inhibitors AZD6244 and trametinib. We present new data showing that MEK 
inhibition leads to an induction of RTK expression and activity that has a functional role 
in resistance. Further when we co-target MEK and RTKs with the pan-RTK inhibitor XL-
184, we improve MEK-induced apoptosis and significantly limit the onset of resistant 
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clones. These data suggest that combined inhibition of MEK and RTK signaling may be 
a rational therapeutic modality in NRAS mutant melanomas.  
 
Results 
AZD6244 inhibits MEK signaling in NRAS mutant melanoma cell lines 
Western Blot studies showed the basal levels of pERK activity was 
heterogeneous across a panel of 14 melanoma cell lines. 7 of these cell lines harbored 
activating BRAF mutations (A375, WM164, SKMEL28, WM1205Lu, WM793, WM9 and 
RPMI7951) and the remaining 7 harbored NRAS mutations (WM1361A, WM1346, 
WM1366, MEL30, M245, M318 and IPC-298) (Figure 16A). Further, NRAS mutant cell 
lines appeared to have lower levels of basal pERK activity compared to their BRAF 
mutant counterparts. Only 2/7 NRAS mutant cell lines had high pERK activity and 2/7 
had medium activity levels. Of the BRAF mutated cell lines, 3/7 possessed high basal 
pERK activity and 3/7 had medium levels. Treatment of a panel of 6 NRAS mutant 
melanoma cell lines with AZD6244 potently inhibited constitutive pERK signaling as 
showing by the reduction in ERK phosphorylation at Thr202/Tyr204 (Figure 16B).  
 
MEK inhibition has only modest effects upon proliferation and survival in NRAS mutant 
melanoma cells 
Despite pERK being inhibited by AZD6244 at nanomolar concentrations, little 
effect was seen upon the proliferation of NRAS mutant cell lines until concentrations 
>1µM, with only 1/7 NRAS mutant cell lines experiencing at least 50% growth inhibition 
at a concentration of 3µM AZD6244 (Figure 17A). 
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Figure 16. AZD6244 potently inhibits pERK in NRAS mutant melanoma cell lines. 
(A) Lysate from a panel of 14 human melanoma cell lines with either BRAF mutations or 
NRAS mutations were collected and immunoblotted to gauge basal pERK activity. (B) A 
panel of 6 NRAS mutant melanoma cell lines were treated with increasing concentration 
of AZD6244 (0-10µM) for 1 hour. Western blotting was performed to interrogate pERK, 
total ERK and GAPDH protein expression levels. 
 
 
Limited effects upon MEK inhibitor-induced apoptosis were observed in a panel of 5 
NRAS mutant melanoma cell lines with less than 40% apoptosis induction achieved in 
2/5 cell lines treated with 3µM AZD6244 (Figure 17B). The 3D organotypic spheroid 
model, which better recapitulates in vivo tumor microenvironment conditions via a 
collagen type IV matrix rather than classic plastic based experiments, also showed little 
cytotoxicity in cells treated with AZD6244 (Figure 17C). Long-term colony formation 
assays where cells were treated chronically with AZD6244 revealed that although 
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AZD6244 had some effect upon inhibiting colony formation, a significant amount of 
resistant clones escaped therapy (Figure 17D).   
 
NRAS mutant melanoma cells have constitutive expression of multiple RTKs  
Western blots studies reveal human melanoma cell lines with NRAS mutations to 
constitutively express high levels of multiple RTKs including c-MET, AXL, PDGFRβ, 
ERBB3, IGF-1Rβ and EGFR (Figure 18A). Analysis of a panel of BRAF mutant 
melanoma cell lines showed that only 1/7 to express AXL, 3/7 to express c-MET and 2/7 
to express EGFR. Whereas, 5/7 NRAS mutant cell lines expressed AXL, 5/7 expressed 
c-MET and 4/7 expressed EGFR. Our results fit with observations in the literatures 
reporting a correlation of AXL and MET with NRAS mutant melanomas [30, 208]. The 
expression of PDGFRβ IGF-1Rβ and ERRB3 was similar between the BRAF and NRAS 
mutant melanoma cell lines. Knockdown of NRAS with siRNA resulted in a decrease in 
the expression of c-MET in 2/3 NRAS mutant melanoma cell lines tested, and 
decreased AXL in 1/3 cell lines, suggesting NRAS may serve a role in the stabilization 
of these RTKs. (Figure 18B). An induction of PDGFRβ was observed in all 3 NRAS 
mutant cell lines following knockdown of NRAS. Further, NRAS mutant melanoma cells 
were also more sensitive to anti-proliferative effects of the pan-RTK inhibitor XL-184 
relative to their BRAF mutant counterparts (Figure 18C). This data suggest NRAS 
mutant melanoma cells may rely upon RTK signaling more heavily relative to their 
NRAS wild type counterparts. 
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Figure 17. The MEK inhibitor AZD6244 suppressed the growth of NRAS mutant 
melanoma cells, but did not prevent the onset of resistant clones 
(A) Increasing concentrations of AZD6244 reduced the growth of NRAS mutant 
melanoma cells. Cells were treated for 72 hours, and cell numbers were quantified 
using Alamar blue assay. (B) A panel of 5 NRAS mutant melanoma cell lines were 
treated for 120 hours with AZD6244 (0-3µM) and stained with Annexin-V. Apoptosis 
was assessed via flow cytometry. (C) Pre-formed spheroids were implanted into 
collagen IV and treated for 120 hours with 1µM AZD6244, before being treated with 
calcein-AM and Ethidium bromide. (D) A panel of NRAS mutant melanoma cell lines 
was treated with vehicle or AZD6244 (1µM) for 4 weeks. After this time, colonies were 
fixed and stained with crystal violet. Photographs are representative of three 
independent experiments. 
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Figure 18. NRAS mutant melanoma cells constitutively express multiple RTKs. 
(A) Western blot showing basal total protein levels of MET, AXL, EGFR, PDGFRβ, IGF-
1Rβ, ERRB3 and GAPDH. (B) NRAS is required for MET expression in a subset of 
NRAS mutant cell lines. M318, WM1361A and WM1366 cells were incubated with 
25nmol/L nontargeting siRNA (NT) or NRAS specific siRNA (NRAS) for 72 hours before 
protein lysate was collected and run on a Western blot to check NRAS, AXL, MET, 
PDGFRβ and GAPDH protein levels.   (C) Increasing concentrations of the pan-RTK 
inhibitor XL-184 reduced the growth of NRAS mutant melanoma cell lines. A panel of 
BRAF mutant (WM164, WM793, WM983A, WM1205Lu) or NRAS mutant (WM1361A, 
WM1366, WM1346, M318) cell lines were treated with drug (1nM - 3µM) for 72 hours, 
and cell numbers were quantified using Alamar blue assay.  
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Inhibition of MEK signaling is associated with adaptive RTK signaling in NRAS mutant 
melanoma 
Multiple studies have reported adaptive RTK signaling as a significant resistance 
mechanism to targeted therapy. In BRAF mutant melanoma, escape from BRAF 
inhibitor therapy has been shown to occur through PDGFRβ [178, 179], IGF-1Rβ [177] 
and MET [180] mediated mechanisms. Further, BRAF inhibitor therapy has also been 
shown to release ERK-dependent feedback loops upon RTKs, which allows for the 
reactivation of ligand-dependent signal transduction [287, 311]. Resistance mechanisms 
to MEK inhibitor therapy have also been reported to rely upon adaptive RTK 
reprogramming in triple-negative breast cancer where an induction of PDGFRβ, 
VEGFR2 and AXL were observed following treatment with the MEK inhibitor AZD6244 
[157]. In light of the evidence showing modulation of RTK expression occurs following 
MAPK inhibition in multiple cancer types, we next investigated whether a similar RTK-
mediated mechanism was playing a functional role within NRAS mutant melanoma cells 
treated with a MEK inhibitor. Treatment of a panel of NRAS mutant melanoma cell lines 
with AZD6244 (1µM, 24 hours) was associated with the increased total protein 
expression of multiple RTKs, including AXL, PDGFRβ and c-MET across the NRAS 
mutant cell line panel (Figure 19A). Similar results were observed in cells treated with 
trametinib (data not shown). The use of phospho-RTK arrays revealed a parallel 
increase in tyrosine phosphorylation of PDGFRβ (WM1361A, WM1366), c-MET 
(MEL30), ERBB2/ERBB3 (M318) and ERBB2/ERRB3/AXL/VEGFR1/IGF-1R (M245) 
(Figure 19B). Further, the MEK-induced increased in tyrosine phosphorylation of 
PDGFRβ, AXL, IGF-1R and ERBB3 were inhibited by treatment with the pan-RTK 
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inhibitor XL-184. One of the most common downstream effector pathways of the RTKs 
induced in response to MEK inhibition is the PI3K/AKT axis [174]. It was noted that 
AZD6244 treatment of WM1361A, WM1366 and WM1346 cells was associated with an 
increase in AKT activity as seen by the increased phosphorylation of AKT at serine 473 
(Figure 19C). In line with the observation that BRAF inhibition can lead to increased 
signaling capability of RTKs [311], it was observed that MEK inhibition enhanced the 
magnitude of growth factor induced AKT signaling in NRAS mutant melanoma cells 
(Figure 19D). AKT activity was increased in cells stimulated with HGF, EGF and PDGF-
BB after 24 hr pre-treatment with AZD6244. Gas6 was not observed to be able to 
increase AKT activity with or without MEK inhibition.  
 
Escape from MEK inhibition can be overcome through suppression of adaptive RTK 
signaling 
Although MEK inhibitors are the first targeted agents to show clinical efficacy in 
patients with NRAS mutant melanoma, no complete responses and only a handful of 
partial responders were observed [146]. We next investigated whether the inhibition of 
adaptive RTK signaling prevented the escape from MEK inhibition. It was noted that 
treatment with the pan-RTK inhibitor XL-184 could block the increase in AKT activity 
associated with MEK inhibition (Figure 20A). The importance of adaptive RTK signaling 
in the escape from MEK inhibition was demonstrated by the ability of XL-184 to 
enhance the cytotoxicity of AZD6244 in a 3D spheroid assay (Figure 20B). 
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Figure 19. MEK inhibition leads to enhanced RTK expression and activity. 
(A) WM1361A, WM1366, WM1346 and M318 cells were treated with AZD6244 (1µM, 0-
72 hours) and Western blotting was performed to detect total AXL, MET, PDGFRβ and 
GAPDH protein expression. (B) Phospho-RTK array analysis of WM1361A, WM1366, 
M318 and MEL30 cells treated with AZD6244 (1µM, 24 hours) reveal increased 
phosphorylated Tyr of multiple RTKs, including AXL, MET, PDGFRβ. (C) WM1361A, 
WM1346 and WM1366 cells treated with AZD6244 (1 µM, 1 hr) have increased AKT 
Ser473 as seen via Western blotting. (D) WM1361A cells were treated for 24 hours with 
1µM AZD6244 in the absence of serum, and subsequently pulsed with 100ng/mL of 
EGF, Gas6, HGF or PDGF-BB for 10 minutes. Lysate was collected and run on a 
Western blot to investigate changes in pAKT Ser473, and total AKT was run as a 
loading control. Three different exposures of pAKT Ser473 are shown. 
	   90 
XL-184 was able to increase the apoptosis induction achieved by the MEK inhibitors 
AZD6244 and trametinib, as seen by annexin V binding and flow cytometry (Figure 
20C). The combination of AZD6244 and XL-184, as well as trametinib and XL-184, was 
able to significantly enhance the prevention of resistant clones in a 4-week colony 
formation assay compared to single treatment of AZD6244, trametinib or XL-184 alone 
(Figure 20D).  
 
Pan-RTK inhibition overcomes resistance to MEK inhibition and NRAS extinction  
 To address functional capacity of RTKs in the resistance phenotype of NRAS 
mutant melanoma cells, cells were first made resistant to MEK inhibition by treating 
them chronically with AZD6244 (5µM) over the course of 3 months and verifying 
resistance via a proliferation assay and Western blotting for pERK and pAKT activity 
relative to parental cells (Figure 21A). The importance of RTKs in the escape from MEK 
inhibition was demonstrated by the ability of XL-184 to reduce the outgrowth of cells 
resistant to MEK inhibition (Figure 21B). A panel of mouse mutant melanoma cells, 
NVCI 2908, NVCI 3267 and NVCI 3019, were created from resistant tumors following 
genetic inhibition of mutant NRAS. Analysis of these cell lines revealed the increased 
expression of multiple RTKs, including MET and PDGFRB (data not shown). Treatment 
of these cell lines resistant to NRAS extinction with XL-184 was able to significantly 
decrease the onset of resistance clones. (Figure 21C). 
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Figure 20. Pan-RTK inhibition enhances efficacy of MEK inhibitors against NRAS 
mutant melanoma cells 
(A) WM1361A cells were treated with AZD6244 (1µM, 0-72 hours) in the presence or 
absence of XL-184 (3µM). Western blotting was performed to check pAKT (Ser473) and 
total AKT. (B) Pre-formed spheroids (WM1361A, WM1366, M318) were implanted into 
collagen IV and treated for 120 hours with AZD (1µM) in the presence or absence of XL-
184 (3µM). Spheroids were subsequently stained with a viability stain. (C) WM1366, 
WM1361A and WM1346 cells were treated with AZD6244 (1-3µM), trametinib (30nM) 
and/or XL-184 (3µM) for 120 hours before being stained with Annexin V. Apoptosis was 
assessed by flow cytometry. (D) WM1366, WM1361A and WM1346 cells were treated 
chronically with AZD6244 (1µM), trametinib (30nM) and/or XL-184 (3µM) for 4 weeks. 
Cells were subsequently stained with crystal violet. 
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Figure 21. pan-RTK inhibition with XL-184 prevents growth of NRAS mutant, MEK 
inhibitor resistant melanoma cells. (A) (Left) WM1361A cells were cultured to 
become resistant to AZD6244, and subsequently found to be cross-resistant to 
trametinib, and validated to be resistant relative to their parental cell line. WM1361A and 
WM1361A Resistant cells were treated with trametinib (0-10µM, 72 hours) and cell 
numbers were quantified with via the Alamar blue assay. (Middle) Western blotting was 
performed on lysate from WM1361A and WM1361A resistant cells to interrogate pERK, 
pAKT and GAPDH. (B) WM1361A Resistant cells were treated with either AZD6244 
(5µM) in the absence or presence of XL-184 (3 µM) chronically for 4 weeks. Cells were 
subsequently stained with crystal violet. (C) NVCI2908, NVCI3267 and NVCI3019 cells 
were treated with XL-184 (3µM) chronically for 4 weeks and subsequently stained with 
crystal violet. 
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Discussion 
 Although remarkable progress has been made recently in providing targeted 
agents to 50% of melanoma patients based off of their BRAF mutant tumor genotype, 
equivalent strategies are completely lacking for BRAF wild type tumors. With the failure 
of targeting essential post-translational modifications critical for NRAS function as well 
as an inability to target the GTPase activity of NRAS, efforts have now concentrated on 
targeting downstream of NRAS and clinical trials have shown the potential utility of 
targeting the MEK/ERK signaling pathways in this genetic subgroup of melanoma [102, 
146, 162]. From clinical experiences in BRAF mutant melanoma patients treated with 
BRAF inhibitors, it is becoming increasingly clear that inhibiting one target will not be 
enough to overcome the highly dynamic, intracellular signaling networks found in 
melanoma cells [287, 311]. The capability to adapt and the inherent pathway plasticity 
has proven critical in the ability of melanoma cells to escape from small molecule kinase 
inhibitors [164]. In melanoma, the phenomena has been most extensively investigated 
in the context of mutant BRAF, where signaling from RTKs has shown to provide vital 
parallel signals that allow BRAF inhibition to be circumvented [177, 179, 180]. Although 
this adaptive signaling has not been explored extensively in NRAS mutant melanoma, it 
is likely to prove equally critical for the development of optimal combinatorial modalities 
that best prevent the onset of resistance.   
 In the present study we evaluated escape mechanisms to MEK inhibition in a 
panel of 7 human NRAS mutant melanoma cell lines treated with the MEK inhibitors 
AZD6244 and (recently FDA approved) trametinib. The panel of NRAS mutant 
melanoma cells was noted to be largely resistant to MEK inhibition, with minimal effects 
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upon apoptosis, proliferation or cytoxicity observed. This is in line with what has been 
reported clinically of MEK inhibitors in NRAS mutant melanoma patients, with no 
complete responders and only a few partial responders in a phase II trial with the MEK 
inhibitor MEK162 [146, 162]. The short progression free survival time is in line with the 
phenomena of resistance in the majority of BRAF mutant melanoma patients treated 
with BRAF inhibitor, despite impressive initial responses [288].  
 There is already evidence from epithelial cancers that ablation of RAS signaling 
is overcome by an upregulation of RTK activity. In colorectal carcinoma, increased AKT 
signaling mediated through IGF-1R has been shown to play a vital role in escape from 
silencing of KRAS with shRNA [312]. In this particular case, the suppression of the 
MAPK pathway from suppression of KRAS leads to the relief of negative feedback 
inhibition mediated by the adaptor protein IRS-1 [312]. In a study of BRAF mutant 
melanoma, it was reported that that inhibition of mutant BRAF lead to the release of 
ERK-dependent negative feedback loops, allowing upregulated activity of multiple RTKs 
to signal downstream upon ligand binding [287, 311]. Similar RTK-mediated resistance 
mechanisms have been observed in triple-negative breast cancer, where inhibition of 
MEK with AZD6244 resulted in the increased expression and activity of multiple RTKs 
including AXL, VEGFR2 and PDGFRβ [157], and in melanoma cells escaping BRAF 
inhibition [256, 311].  
 Under basal conditions, BRAF mutant melanoma cells are not sensitive to the 
mitogenic effects of exogenous growth factors, due to ERK-mediated negative feedback 
loops that prevent RTKs from signaling downstream upon ligand binding, in an attempt 
by the cell to limit RAS activity [311]. However, following inhibition of BRAF, the 
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feedback inhibition is relieved through the decreased expression of the negative 
pathway regulator Spry-2 [287, 311]. This mechanism allows for BRAF mutant 
melanoma cells to become sensitive to the mitogenic effects of ligand binding to RTKs, 
due to the ability of RAS to become active in the absence of the ERK-dependent 
negative feedback. In this study we demonstrate for the first time that a similar 
depression of feedback inhibition occurs in NRAS mutant melanoma following MEK 
inhibition. There is already substantial evidence that MAPK signaling differs slightly 
between BRAF and NRAS mutant melanoma cells [118]. In NRAS mutant melanoma, 
CRAF is utilized rather than BRAF to signal downstream, due to the inactivation of 
BRAF in ERK-mediated feedback loops and the deregulation of PKA signaling, which 
ultimately prevents PKA from phosphorylating CRAF at its two inhibitory sites (Ser43 
and Ser223) [102, 118].  
Melanoma cell lines and tumor specimens have been shown to possess a large 
number of cell surface growth factor receptors, all with the capability of conferring 
resistance to targeted therapy [174, 175]. The precise characterization of those RTKs 
that are most critical for driving innate resistance to small molecule kinase inhibitors has 
not yet been realized. An analysis of a panel of 14 human melanoma cell lines (7 
possessing BRAF mutations and 7 possessing NRAS mutations) revealed the 
constitutive expression of c-MET, PDGFRβ, AXL, EGFR and IGF-1Rβ. Further, 
enhanced RTK activity by way of increased tyrosine phosphorylation of PDGFRβ, 
VEGFR1 and ERBB3 was observed following treatment with the MEK inhibitor 
AZD6244 (selumetinib). Reciprocal increases in ERBB3, EGFR, IGF1R and AXL 
expression were also noted following treatment with the FDA-approved MEK inhibitor 
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trametinib and after knockdown of NRAS using siRNA (data not shown). XL-184 
(cabozantinib) is a small molecule kinase inhibitor with high affinity against c-MET, RET, 
KIT, FLT-1, FLT-3, FLT-4, TIE2 and AXL, as well as slightly weaker activity against 
PDGFRβ. A recent phase II randomized trial reported tumor regression in 55% of 
melanoma patients treated with XL-184, with an objective response rate of 5% [313]. 
There was no correlation between response and BRAF mutational status. In cell culture 
assays, XL-184 was capable of abrogating the increases in RTK tyrosine 
phosphorylation associated with MEK inhibitor treatment. XL-184 was able to block the 
increase in AKT activity observed with MEK inhibition and was associated with 
increased cytotoxicity in 3D spheroids, increased apoptosis in flow cytometry 
experiments and an enhanced inhibition in the onset of resistant clones in long-term 
colony formation assays. XL-184 enhanced the efficacy of AZD6244, as well as 
trametinib. The observation that RTK inhibitors may prevent the onset of resistance is 
supported by preclinical studies of BRAF-mutant colorectal carcinoma, breast cancer, 
and KRAS mutant colon cancer showing that RTK inhibitors (EGFR/HER kinase, IGF-
1R and pan-RTK) increase the efficacy of MAPK inhibition strategies [157, 311, 312, 
314].  
The current clinical approach to treating NRAS mutant melanoma patients is 
focused upon targeting multiple pathways known to be downstream of RAS including 
PI3K and MEK (BKM120+MEK162 and BYL179+MEK162) and PI3K+mTOR 
(BEZ235+MEK162). There is already preclinical evidence that co-targeting PI3K and 
MEK, as well as PI3K/mTOR/MEK can generate cytostasis or regression in NRAS 
mutant melanoma xenograft models [147, 300]. Another approach has utilized a 
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comprehensive bioinformatics approach to investigate critical nodes important for RAS 
driven melanoma that are missed from MEK inhibition. The study suggested the 
potential utility of co-targeting CDK4 along with MEK in NRAS mutant melanoma, and 
clinical trials have been launched to investigate this strategy [315]. In this study, we 
show for the first time the importance of adaptive RTK signaling in the escape of NRAS 
mutant melanoma from the inhibition of MEK. Our results provide the first rationale for 
the co-targeting of both RAS/MEK/ERK and RTK signaling.  
 
Materials and Methods 
Drugs 
Trametinib was purchased from ChemieTek (Indianapolis, IN). AZD6244 and XL-
184 were purchased from Selleck Chemical (Houston, TX). 
 
Melanoma cell lines and culture conditions 
Human melanoma cell lines A375, WM164, SKMEL28, WM1205Lu, WM793, 
WM9, RPMI7951, WM1361A, WM1346, WM1366, SK-MEL30, M245, M318 and IPC-
298 have been described and were maintained in RPMI-1640 with 5% FBS, at 37°C 
with 5% CO2. NVCI-2908, NVCI-3019 and NVCI-3267 mouse melanoma cell lines were 
provided by Dr. Sheri Holmen (Huntsman Cancer Institute, Salt Lake City, UT) and cells 
were maintained in 254 medium containing human melanocyte growth supplement 
(HMGS), 10% FBS and 50 µg/mL gentamycin at 37°C with 5% CO2. 
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siRNA experiments 
Human melanoma cell lines were plated in 6-well plates at 1.5 x 105 cells per well 
and allowed to adhere overnight. The following day, RPMI complete media was 
replaced with Opti-MEM (Invitrogen) and 25nmol/L NRAS si (Dharmacon, Thermo-
Fisher, Pittsburg, PA) was transfected using Lipofectamine (Invitrogen). Scrambled 
siRNA at 25nmol/L was also added as a non-targeting control. A final concentration of 
5% FBS in complete RPMI was added the next day. Cells were transfected for a total of 
72 hours.  
 
Immunoblotting 
Blots were immunostained using the following primary antibodies from Cell 
Signaling Technologies: MET (8198), EGFR (2085), ERBB3 (HER3:4754), AXL (4566), 
PDGFRβ (3162), IGF-1Rβ (9750), PTEN (9188), phospho-ERK (9106) and total ERK 
(9102). NRAS primary antibody was purchased from Santa Cruz Biotechnology and 
GAPDH (G8795) was purchased from Sigma. Detection was performed using anti-
mouse or anti-rabbit IgG-HRP secondary antibodies as appropriate (Cell Signaling. The 
blots were incubated in ECL solutions per the manufacturer’s specifications (Amersham, 
Piscataway, NJ) and exposed to film. 
 
Phospho antibody arrays 
The human Phospho-RTK Array Kits (ARY001; R&D Systems, Minneapolis, MN) 
were used to determine the relative tyrosine phosphorylation states of 49 distinct RTKs 
according to the manufacturer’s protocol. Briefly, human melanoma cell lines were 
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maintained in RPMI supplemented with 5% FBS. After incubating the cells with vehicle 
(dimethyl sulfoxide (DMSO)), 1 µM AZD6244, 3 µM XL-184 or the combination of 
AZD6244 and XL-184 for 72 hours, lysates were prepared using lysis buffer 17 (1% NP-
40, 50 mM Tris-Hcl pH 8.0, 100 mM sodium fluoride, 30 mM sodium pyrophosphate, 2 
mM sodium molybdate, 5 mM EDTA, 2 mM sodium orthovanadate) containing protease 
inhibitors (Protease Inhibitor Mini tablets, Pierce, Rockford, IL). The arrays were 
incubated with 1000 µg of protein lysate overnight at 4°C after blocking for 1 hour with 
Array Buffer 1 (R & D Systems). The arrays were subsequently washed and incubated 
with a horseradish peroxidase-conjugated phospho-tyrosine detection antibody (R&D 
Systems). Detection was performed using chemiluminescence (Chemi Reagent Mix, 
R&D Systems) and the arrays were exposed to film (BioMax Light, Rochester, NY). The 
intensity of each phospho-RTK array signal was measured using ImageJ and the 
relative intensities of the averaged signal from each pair of duplicate spots were 
determined in relationship to the negative control spots.  
 
Proliferation assays 
MTT assays were performed as follows. Cells were plated 2,000 per well in a 96-
well cell culture plate and allowed to adhere over night. After 24 h, cells were treated 
with increasing concentrations of AZD6244 (0-30 µM ) over the course of 72 h. After 
treatment, proliferation was quantified by using Alamar Blue from Life Technologies 
according to the manufacturers instruction and absorbance of the stain was read using 
a plate reader.   
 
	   100 
Colony formation assays 
Cells were plated in 6-well plates at 2 x 104 per well and allowed to adhere 
overnight. The following day, media with vehicle (DMSO), 1 µM AZD6244, 3 µM XL-
184, 30 nM Trametinib, or the combination of AZD6244 and XL-184, or the combination 
of Trametinib ad XL-184 were added and replaced twice a week. After 4 weeks, the 
plates were stained with crystal violet. Relative colony density was determined by 
solubilizing the crystal violet dye in 10% acetic acid followed by measurement of 
absorbance at 450 nm.  
 
Flow cytometry 
Cells were plated in 6-well plates at 1.5 x 105 cells were well and allowed to 
adhere overnight. The following day cells were treated with vehicle (DMSO), 1 µM 
AZD6244, 3 µM XL-184, 30 nM Trametinib, or the combination of AZD6244 and XL-184, 
or the combination of Trametinib and XL-184. After 120 hours of treatment, cells were 
harvested and subsequently stained with Annexin-V and apoptosis was assessed via an 
LSR-II flow cytometer. Results were analyzed with flowjo and results representing the 
mean ± S.E.M. from 3 independent experiments are shown. 
 
3D spheroid assays 
Melanoma spheroids were prepared using the liquid overlay method [316]. 
Spheroids were either treated for 120 hours with vehicle (DMSO), 1 µM AZD6244, 3 µM 
XL-184 or the combination of AZD6244 and XL-184. Spheroids were subsequently 
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washed with cold sterile PBS, stained with a Viability Kit (Invitrogen) per manufacturer’s 
instructions and imaged using an inverted Zeiss fluorescence microscope. 
 
Statistical analysis 
For colony formation, proliferation and apoptosis assays, each cell line was 
assayed according to the n indicated and the data is represented as the mean ± S.E.M. 
Student’s t test was used to determine significance.  
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Chapter 4 
Recovery of phospho-ERK activity allows NRAS mutant melanoma cells to 
escape from MEK inhibitor therapy 
 
Introduction 
Patients whose melanomas are NRAS mutant suffer the worse overall prognosis 
compared to their BRAF mutant and BRAF/NRAS wild type counterparts, and effective 
targeted therapy for this subgroup have yet to be discovered [124]. To date the only 
successful targeted approach reported for NRAS mutant melanoma has been a phase II 
trial that utilized the MEK inhibitor MEK162, which resulted in 20% of patients 
experiencing a partial response and 63% achieving disease control [146]. Although 
promising, no complete responses were attained and strategies to extend the durability 
of MEK inhibition are urgently needed for this subgroup of melanomas. 
Small molecule kinase inhibitors of the MAPK pathway have been extensively 
studies in the context of melanoma and a diverse array of resistance mechanisms have 
been characterized, which include both intrinsic and acquired mechanisms of resistance 
[82, 89, 93, 317]. One of the most significant discoveries shown to blunt the effects of 
BRAF inhibition is the rapid reactivation of ERK activity following inhibition of BRAF in 
BRAF mutant melanoma cells [164]. Reactivation of MAPK kinase signaling is also a 
phenomenon observed in the majority of patients failing on single agent therapy with 
BRAF inhibitor [288].  It was demonstrated that complete pharmacologic inhibition 
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(>80%) of pERK in tumors of patients correlated with clinical response [317]. The 
addition of a MEK inhibitor to BRAF inhibitor therapy yielded more durable responses 
relative to patients treated with mono-therapy BRAFi, implicating the necessity of 
complete pathway ablation for best clinical durability [3, 100, 146, 288]. Accordingly, the 
success of vertically targeting the MAPK pathway lead to the FDA approval of the MEK 
inhibitor trametinib plus BRAF inhibitor dabrafenib combination in 2013, for the 
treatment of BRAF mutant melanoma. BRAF mutant melanoma patients treated with the 
combination of dabrafenib and trametinib experienced median progression free survival 
of 9.4 months compared with 5.8 months in the monotherapy group [288]. The rate of 
complete or partial response with the combination of dabrafenib and trametinib was 
reported to be 76% compared with 54% with dabrafenib monotherapy [3, 288].  
Little is known whether similar adaptive MAPK reactivation mechanisms exist in 
NRAS melanoma cells in response to MAPK pathway inhibition and such phenomenon 
have not been well characterized in the literature. In the current study we report a robust 
reactivation of pERK activity following MEK inhibition with the MEK inhibitors AZD6244 
and trametinib. Reactivation of pERK was a mechanism of early therapy escape and 
combined MEK/ERK inhibition was shown to both enhance the levels of apoptosis and 
abrogate the onset of resistance. 
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Results 
AZD6244 and trametinib potently inhibited pERK activity across a panel of  
NRAS mutant melanoma cell lines 
AZD6244 (ARRY-142886, selumetinib) and trametinib (GSK1120212, JTP-
74057) are allosteric, second generation, ATP non-competitive inhibitors with 
nanomolar activity against MEK1/2 [318, 319]. Treatment of a panel of five NRAS 
mutant melanoma cell lines with either AZD6244 or trametinib potently inhibited pERK 
signaling in all cell lines. (Figure 22A). Long-term colony formation assays revealed that 
MEK inhibition with either AZD6244 or trametinib reduced the number of growth of 
WM1361A, WM1366 and WM1346 cells, however a significant number of resistant 
clones remained after 4 weeks of chronic treatment (Figure 22B).  
 
Prolonged MEK inhibition leads to a recovery of pERK signaling 
Previous reports have demonstrated that inhibition of MAPK activity is often 
overcome with reactivation of the pathway [311]. ERK signaling has been shown to 
rebound within 72 hours of BRAF inhibition in BRAF mutant melanoma cells [164] and 
ERK has also been shown to rapidly recover after MEK inhibition with AZD6244 in 
triple-negative breast cancer cells [157]. To investigate whether a similar phenomenon 
was occurring within our NRAS mutant melanoma cell line panel, we next studied the 
time course of signaling recovery. Treatment of drug-naïve WM1361A, WM1366, 
WM1346 and M318 with AZD6244 (1 µM) showed the pathway to be rapidly inhibited, 
with robust recovery of pERK signaling within 24-48 hours in the majority of cell lines 
(WM1361A, WM1366 and WM1346) (Figure 23A). 
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Figure 22. AZD6244 and trametinib potently inhibit pERK activity, however cells 
escape MEKi treatment. (A) A panel of NRAS mutant melanoma cell lines (WM1361A, 
WM1366, WM1346, M202, and M318) was treated with AZD6244 (1µM, 1hour) or 
trametinib (30nM, 1hour). Western blotting was performed to interrogate pERK and total 
ERK levels. (B) WM1361A, WM1366 and WM1346 cells were treated chronically for 4 
weeks with 1 µM AZD6244 or 30 nM trametinib in a colony formation assay. Cells were 
subsequently stained with crystal violet. 
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Rapid and robust pERK reactivation was also noted in cells treated with the MEK 
inhibitor trametinib (30nM, 0-72 hours) (Figure 23B). Cell cycle analysis of WM1361A 
and WM1366 cells treated with AZD6244 (1µM, 0-48 hours) revealed that although 
MEK inhibition leads to a reduction in percentage of cells cycling through S-phase after 
24 hours of treatment, a greater percentage of cells were observed cycling through S-
phase after 48 hours of treatment, occurring in parallel to MAPK pathway reactivation 
(Figure 23C). Similar results were observed in cell cycle analysis of cells treated with 
trametinib (data not shown). The results suggested pERK reactivation to play a 
functional role in cell cycle re-entry of cells treated with MEK inhibition. 
 
Rebound pERK treatment allows for escape from cell cycle arrest 
 Having demonstrated that pERK signaling recovered within 72 hours of MEK 
inhibition with either AZD6244 or trametinib, we next determined the utility of dual 
MEK/ERK inhibition in preventing escape from single agent MEKi to define the function 
rebound pERK was playing. We leveraged the novel ERK inhibitor VTX-11e [320]. A 
time course treatment of WM1361A and WM1366 cells with AZD6244 was observed to 
initially inhibit phosphorylation of the ERK substrate RSK-1 below detectable levels, 
however pRSK1 (Thr359/Ser353) was observed to recover, mirroring reactivation in 
pERK (Figure 24A). Cyclin D1 expression was observed to persist in WM1361A cells 
and appeared to recover following an initial decrease in WM1366 cells treated with 
AZD6244. 
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Figure 23. Robust reactivation of ERK signaling and cell cycle re-entry occurs in 
cells treated with either AZD6244 or trametinib. (A) WM1361A, WM1366, WM1346 
and M318 cells were treated with 1 µM AZD6244 (0-72 hours) before cells were 
harvested and lysate was immunoblotted for pERK and total ERK. (B) WM1361A cells 
were treated with 30 nM trametinib (0-72 hours) and lysate was subsequently 
immunoblotted for pERK and total ERK. (C) WM1361A and WM1366 cells were treated 
with 1 µM AZD6244 (0-48 hours). Cells were harvested and stained with PI for cell cycle 
analysis by flow cytometry. 
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The addition of VTX-11e to AZD6244 prevented reactivation of p- RSK-1 
(Thr359/Ser353) and potently abrogated cyclin-D1 expression below detectable levels 
(Figure 24A). Further the combination of AZD6244 and VTX-11e reduced expression of 
cyclin-D1 and pRB protein phosphorylation, and induced a greater level of the CDK 
inhibitor p27 than either agent could accomplish alone (Figure 24B). The combination of 
VTX-11e with either AZD6244 or Trametinib better prevented the percentage of cells 
cycling through the S-phase and yielded a profound G1-phase cell cycle arrest (Figure 
24C).  
 
Combined MEK/ERK inhibitor treatment increases apoptosis induction and prevents the 
acquisition of resistance 
We next investigated whether the co-targeting of MEK and ERK would abrogate 
the MAPK-dependent escape from MEK inhibitor therapy and studied whether this 
would impede the onset of resistance. The treatment of WM1361A cells with the 
combination of AZD6244 and VTX-11e caused the greatest induction of apoptosis, as 
seen by BIM and cleaved Parp expression levels, compared to what was achievable by 
AZD6244 or VTX-11e alone (Figure 25A). Similar apoptotic effects were observed when 
WM1361A, WM1366 and WM1346 cells were treated with AZD6244, trametinib, VTX-
11e or the combination of AZD6244 and VTX-11e, or the combination of trametinib and 
VTX-11e (Figure 25B). Although VTX-11e induced greater levels of apoptosis as a 
single agent compared to AZD6244 or trametinib, the combination of VTX-11e with 
either MEK inhibitor led to a significantly greater apoptotic response compared to either 
agents alone (Figure 25B). 
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Figure 24: Rebound pERK signaling functions in the escape from MEK inhibitor-
induced cell cycle arrest. (A) WM1361A and WM1366 cells were treated with 1 µM 
AZD6244 in the presence or absence of 300 nM VTX-11e (0-72 hours). Cells were 
subsequently harvested, lysate was prepared and immunoblotted for pERK, pRSK1 
(Thr359/Ser363) and cyclin D1. (B) WM1361A cells were treated with 1 µM AZD6244, 
300 nM VTX-11e or the combination of AZD6244 with VTX-11e for 72 hours. Lysate 
was immunoblotted for pERK, pRSK1 (Thr359/Ser363), phospho-pRB, total pRB, p27 
and cyclin D1. (C) WM1361A and WM1366 cells were treated with 1 µM AZD6244, 30 
nM trametinib, 300 nM VTX-11e, or the combination of AZD6244 with VTX-11e, or the 
combination of trametinib with VTX-11e for 48 hours before being stained with PI for cell 
cycle analysis via flow cytometry. 
 
 
It was further found that the combination of VTX-11e with AZD6244 and the 
combination of VTX-11e with trametinib better prevented the onset of resistant clones in 
colony formation assays relative to what each inhibitor could accomplish as single agent 
(Figure 25C). 
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Figure 25. Dual MEK/ERK inhibitor therapy better prevents escape from MEK 
inhibition. (A) WM1361A cells were treated with vehicle (DMSO), 1 µM AZD6244, 300 
nm VTX-11e or the combination of AZD6244 and VTX-11e for 72 hours. Lysate was 
immunoblotted for BIM and Parp cleavage. (B) WM1361A, WM1366 and WM1346 cells 
were treated with vehicle (DMSO), 300 nM VTX-11e, 1 µM AZD6244, 30 nM trametinib, 
or the combination of AZD6244 and VTX-11e, or the combination of trametinib and 
VTX-11e for 72 hours. Cells were stained with Annexin-V and apoptosis was assessed 
by flow cytometry. (C) WM1361A, WM1366 and WM1346 cells were treated with vehicle 
(DMSO), VTX-11e (100-300 nM), 1 µM AZD6244, 30 nM trametinib, or the combination 
of AZD6244 and VTX-11e, or the combination of trametinib and VTX-11e chronically for 
4 weeks, and subsequently stained with crystal violet. 
 
 
Discussion 
Following the success of targeted therapy agents such as vemurafenib [2], and 
the combination of dabrafenib and trametinib [288] in BRAF mutant melanoma, there is 
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now hope that NRAS mutated melanomas may be susceptible to similar therapeutic 
strategies. Although the initial reports showed clinical activity of MEK inhibition in 
melanoma patients with NRAS mutant melanoma, the effects were transient with 
median duration of response a mere 7.6 weeks [146]. With the short window of 
progression free survival from MEK inhibitor treatment, indications suggest that most 
MEK162-treated patients eventually become resistant. In the current study, we focused 
on the earliest stages of therapy escape after treatment with the MEK inhibitors 
AZD6244 and recently FDA approved trametinib. Through an initial series of 
experiments we demonstrated AZD6244 and trametinib potently inhibited pERK activity 
across a panel of NRAS mutant melanoma cells, however were unable to induce 
significant levels of apoptosis, and a significant number of resistant clones persisted 
after chronic treatment in colony formation assays.  
 Currently, very little is known about the mechanism of early escape of NRAS 
mutant melanoma cells from MEK inhibitor treatment. A lesson learned from how BRAF 
mutated melanoma cells escape BRAF inhibition is that intracellular signaling networks 
are highly dynamic and this pathway plasticity allows the capability to rapidly adapt to 
small molecule kinase inhibitors [163, 164, 287, 311]. Signaling from RTKs in response 
to BRAF inhibitor treatment has been demonstrated to provide BRAF mutant 
melanomas vital adaptive signaling to circumvent treatment [180, 287, 311]. Pathway 
reactivation in BRAF mutant melanoma has also been shown to play a significant role in 
the escape of cells to therapy, with the proof of principle clinical trial combining the 
BRAF inhibitor dabrafenib with the MEK inhibitor trametinib yielding remarkable a 76% 
response rate, compared with 54% with dabrafenib monotherapy [3, 164]. Clearly, 
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vertically targeting the MAPK pathway has been proven far more effective in the clinical 
setting compared to any other BRAF inhibitor combination currently being explored, to 
date. In non-melanoma systems, treatment with the MEK inhibitor AZD6244 leads to 
resistance associated with increased RTK expression and pERK reactivation [157]. In 
NRAS mutant melanoma, it has been recently suggested that CDK4 served as a key 
driver in cells escaping MEK inhibitor therapy [315].  
 This study makes the observation that combined MEK and ERK inhibitor 
treatment enhances the levels of apoptosis in NRAS mutant melanoma cells before 
resistance to MEK inhibition is even acquired. The observation that dual targeting of 
MEK and ERK blocks colony formation also suggests that the rebound pERK signalling 
observed serves a critical escape mechanism from MEK inhibitor therapy. Although the 
idea of targeting the same pathway at two different nodes may seem redundant, it has 
been clinically successful in the setting of BRAF mutant melanomas and may improve 
pathway inhibition through the prevention of negative feedback loops that have been 
demonstrated to be relieved following pathway blockade at a single point [321]. 
Interestingly, there exists the possibility that MEK and ERK inhibitors may hit subtly 
different cellular targets. And although it has not yet been reported in the literature [153], 
it is possible that MEK may have targets other than ERK, explaining why co-targeting 
MEK and ERK yielded increased Parp cleavage, increased expression of the pro-
apoptotic BCL-2 family member BIM, and a significantly higher induction of apoptosis 
compared to what was achievable by MEK or ERK inhibitor alone.  
 The finding that co-targeting MEK and ERK prevents the onset of resistance in 
our in vitro system melanoma models argues that ERK inhibitors may be of use in 
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enhancing clinical efficacy of MEK inhibitors, and may delay or even prevent the onset 
of resistance in some cases. Studies show MAPK activity drives the proliferation of 
melanoma cells through the suppression of the cyclin-dependent kinase inhibitor p27KIP1 
and through the increased expression of cyclin D1 [164, 322]. Further, only small levels 
of MAPK pathway activity are required for maintaining cyclin D1 levels and cell cycle 
entry [164, 322]. Consistent with our data, cells treated with MEK inhibitor reactivated 
the MAPK pathway and re-entered the cell cycle after 48 hours, correlating with a 
rescue of cyclin D1 expression. The co-targeting of MEK and ERK abrogated cell cycle 
entry, pathway reactivity and cyclin D1 expression. Cyclin D1 partly stimulates cell cycle 
progression through inhibitory phosphorylation (partial inactivation) of RB in mid-G1 
[323, 324]. RB plays a major role in cell cycle progression by inhibiting E2F activity and 
inducing growth arrest [323, 325]. The combination of MEK and ERK inhibition was 
associated with the greatest increase of CDK inhibitor p27kip1 and hypo-phosphorylation 
(reactivation) of pRB relative to what was achievable from MEK or ERK inhibition alone. 
These findings provide strong rationale for the testing of combined MEK and ERK 
inhibitors in the clinical management of patients whose melanomas are NRAS mutant.  
 
Materials and Methods 
Melanoma cell lines 
 The melanoma cell lines WM1361A, WM1366 and WM1346 were a gift from Dr. 
Meenhard Herlyn (The Wistar Institute, Philadelphia, PA) and were grown in RPMI 
supplemented with 5% fetal bovine serum. The melanoma cell lines M202 and M318 
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were a kind gift from Dr. Antoni Ribas (The Jonsson Comprehensive Cancer Center, 
Los Angeles, CA).  
 
Western blotting 
 Cells were plated 500,000 per 10 cm cell culture petri dish and allowed to adhere 
over night. The next day, cells were treated with 1 µM AZD6244, 30 nM trametinib, 300 
nM VTX-11e, or the combination of AZD6244 and VTX-11e (0-72 hours). Cells were 
subsequently harvested from cell culture plates using 0.25% trypsin and protein lysate 
was purified using a RIPA digest. Lysate was then loaded into 10, 12 or 15 well gels 
and then transferred onto membranes. Membranes were activated in methanol, allowed 
to dry for 15 minutes and then blocked for one hour in a solution of 5% dried non-fat 
milk in TBST. After blocking, membranes were briefly washed in TBST, primary 
antibodies were suspended in a 1:1000 dilution in either 5% dried non-fat milk in TBST 
or 5% BSA in TBST according to the manufacturers instructions. Primary antibodies 
were allowed to incubate over night at 4°C. The next day, membranes were washed for 
15 minutes three times with TBST. Mouse or rabbit secondary antibody was suspended 
in a 1:2000 dilution in 5% dried non-fat milk in TBST according to the species of primary 
antibody used. Membranes were incubated in secondary antibody for an hour on a 
shaker at room temperature and subsequently washed with TBST for 20 minutes three 
times. Membranes were than developed using ECL and film. The antibodies to 
phospho-ERK, total ERK, pRSK-1, total RSK1, Cyclin D1, BIM, pRB, Rb, p27 and 
cleaved-Parp were purchased from Cell Signaling Technology. GAPDH was purchased 
from Sigma. 
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Flow cytometry  
 Cells were plated 150,000 per well in a 6-well cell culture plate and allowed to 
adhere overnight. The next day cells were treated with 1 µM AZD6244, 30 nM 
trametinib, 300 nM VTX-11e, or the combination of AZD6244 and VTX-11e, or the 
combination of trametinib and VTX-11e (0-72 hours) before being harvested using 
0.25% trypsin. Cells were pelleted with a centrifuge, supernatant was aspirated and 
cells were pashed with 1 mL of annexin V binding buffer. Cells were pelleted once 
more, supernatant aspirated, resuspended in 50uL of annexin-V binding buffer and 
transferred to facs tubes. Cells were stained with Annexin-V and TMRM for 15 minutes 
at 37°C and then passed through a cell strainer to attain a single cell suspension for 
apoptosis analysis by LSR-II flow cytometer.  
 For cell cycle analysis, cells were treated with 1 µM AZD6244, 30 nM trametinib, 
300 nM VTX-11e, or the combination of AZD6244 and VTX-11e, or the combination of 
trametinib and VTX-11e (0-48 hours) before being stained with propidium iodide (GET 
STAIN INFO) according to manufacturer’s instructions. Cells were passed through cell 
strainer to attain a single cell suspension for cell cycle analysis by a Canto flow 
cytometer.  
 
Colony formation assay 
Cells were plated in 6-well plates at 2 x 104 per well and allowed to adhere 
overnight. The following day, media with vehicle (DMSO), 1 µM AZD6244, 30 nM 
Trametinib, 300 nM VTX-11e, or the combination of AZD6244 and VTX-11e or the 
combination of trametinib and VTX-11e were added and replaced twice a week. After 4 
	   116 
weeks, the plates were stained with crystal violet. Relative colony density was 
determined by solubilizing the crystal violet dye in 10% acetic acid followed by 
measurement of absorbance at 450 nm.  
 
Statistical analysis 
 Data show the mean of at least 3 independent experiments. GraphPad Prism 5 
statistical software was used to perform the Student’s t test where (*) indicates P≤0.05, 
(**) indicates 0.05 ≤	  P ≤	  0.01, (***) indicates P≤0.001 and (****) indicates P≤0.0001. 
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Chapter 5 
 Summary, Final Discussion, and Future Work 
 
Summary and Discussion 
 Our work has delineated adaptive (and tractable) resistance mechanisms 
occurring in BRAF wild type melanoma cells in response to chemotherapy and targeted 
agents. Currently there are no targeted therapy regimens (single agent or combination) 
that effectively and durably improve BRAF wild type melanoma patient outcome, making 
these investigations critical in the formulation of future therapeutic strategies. First, AKT 
inhibition significantly enhances the long-term cytotoxic and anti-proliferative effects of 
carboplatin and paclitaxel treatment in BRAF/NRAS wild type melanoma cells (Chapter 
2). AKT inhibition and chemotherapy induces autophagy, which functionally protects 
melanoma cells from ROS-mediated cytotoxicity, revealing a key resistance mechanism 
to the treatment combination (Chapter 2). Second, a subset of NRAS mutant 
melanomas were largely insensitive to the apoptotic and anti-proliferative effects of 
MEK inhibitors, and escaped through the adaptive RTK upregulation in response to 
MAPK pathway inhibition (Chapter 3). Third, MEK inhibitors cooperate with ERK 
inhibition to abrogate the onset of MEK inhibitor resistant NRAS mutant melanoma cells 
(Chapter 4).  
 We have demonstrated the AKT pathway serves as an escape mechanism to 
chemotherapy in BRAF/NRAS wild type melanoma, and autophagy serves as an 
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adaptive resistance mechanism to concurrent AKT inhibition and chemotherapy. We 
found that inhibiting autophagy enhanced the cytotoxicity induced from either 
chemotherapy or AKT inhibition, however the greatest effect was seen when autophagy 
was inhibited in the context of concurrent AKT inhibition and chemotherapy exposure. 
The cytotoxic effects of concurrent treatment with AKT inhibition and chemotherapy 
were not toxic to normal stromal fibroblasts. Additionally, since neither single agent AKT 
inhibition or chemotherapy are effective at durably reducing tumor burden in melanoma 
patients, the potential cooperation shown in our studies is highly relevant in the 
melanoma field. Combination treatment with AKT inhibitors may sensitize BRAF/NRAS 
wild type melanomas to chemotherapeutic intervention. The addition of an autophagy 
inhibitor will likely abrogate the resistance mechanisms we have characterized in our 
study. 
 An important aspect of our work hinges upon the mechanistic insight underlying 
why single agent MEK inhibition has not produced long lasting effects in clinical trials for 
NRAS mutant melanoma patients. We identified two independent adaptive resistance 
mechanisms that lead to escape of NRAS mutated melanoma cells from the MEK 
inhibitors AZD6244 and trametinib. MEKi-mediated induction of RTK activity was 
functional, where pan-RTK inhibition prevented the onset of MEK resistant clones in 
long-term colony formation assays, as well as inhibited the growth of NRAS mutated 
melanoma cells with acquired MEK inhibitor resistance. The rapid recovery of pERK 
activity in response to MEK inhibition was functionally important, and the co-targeting 
MEK and ERK led to significant apoptosis and cell cycle arrest. Taken together our data 
suggests the addition of a pan-RTK inhibitor or ERK inhibitor may enhance the clinical 
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activity of MEK inhibition by increasing treatment-induced cell death and preventing the 
adaptive mechanisms shown to functionally confer resistance. Further investigation is 
needed to determine whether therapeutic benefit from these treatment combinations 
outweigh any unforeseen patient toxicities. Data from patients treated with BRAF and 
MEK inhibitors is encouraging and suggests vertical targeting of the MAPK pathway can 
be achieved without excessive toxicity. 
 In summary, we hypothesize that AKT inhibition amplifies the cytotoxic effects of 
chemotherapy in BRAF/NRAS wild type melanoma cells, and the addition of an 
autophagy inhibitor may be one strategy to increase the anti-tumor potency of this drug 
cocktail, ultimately improving clinical activity in patients whose melanomas are 
BRAF/NRAS wild type. We postulate the addition of either a pan-RTK inhibitor or ERK 
inhibitor to MEK inhibitor therapy may increase the clinical durability and response of 
this strategy to improve the lives of NRAS mutant melanoma patients. 
 
Future Work 
 We are actively expanding on our findings where chemotherapeutic efficacy was 
improved with the addition of an AKT inhibitor by optimizing the sequence of treatment 
administration. The treatment regimen used within our experiments recapitulated how 
the patients were treated in the phase I clinical trial of MK-2206 plus carboplatin and 
paclitaxel, where patients were concurrently treated with AKT inhibitor and 
chemotherapy followed by maintenance AKT inhibitor. Concurrent versus sequential 
treatment regimens are being explored and mathematically modeled with the Integrative 
Mathematical Oncology group at the Moffitt Cancer Center to identify optimized 
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treatment regimens, which will ideally predict best responders to treatment. Flow 
cytometry assays are being leveraged to delineate the effect treatment-induced 
autophagy confers upon proliferation and apoptosis in a mixed population of cells.   
The NRAS mutant melanoma work presented in this dissertation promotes 
additional investigation focused upon the potential capacity of pERK reactivation in the 
observed MEKi-mediated upregulation in RTK activity. Preliminary studies demonstrate 
pan-RTK inhibition to have no effect upon pERK reactivation, and conversely ERK 
inhibition to not prevent MEKi-induced increase in RTK expression, suggesting these 
two adaptive resistance mechanisms to be independent of one another (data not 
shown). CDK2 and PI3K/AKT/mTORC1 signaling have also demonstrated functional 
roles in the escape of NRAS mutated melanoma cells to MEK inhibitor therapy, however 
the optimal combination regimen has yet been determined on the clinical stage. We 
would like to address the utility of each of these resistance mechanisms, in turn, to 
determine if MEK inhibition is optimally improved with targeting multiple MEK resistance 
mechanisms described, or ideally one key pathway. We will also analyze the effects of 
these different treatment modalities in NRAS-driven murine models, as well as expand 
our studies with primary patient samples to determine the translational relevance of our 
findings.  
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Figure 26. Scheme for observed MEK inhibitor resistance mechanisms. Treatment 
of a panel of NRAS mutant melanoma cells revealed two independent adaptive 
resistance mechanisms to play a functional role in determining sensitivity to MEK-
induced cytotoxicity. (Upper) A robust induction of RTK activity and expression allowed 
the outgrowth of MEK resistant cell lines in long-term colony formation assays. 
Resistance was reversible and could be abrogated through co-targeting MEK and RTK 
activity (Chapter 3) (Lower) MAPK pathway reactivation in response to MEK inhibition 
played a functional role, allowing cell cycle re-entry and long-term survival. Co-targeting 
MEK and ERK concurrently abrogates cell cycle re-entry, reinforces cell cycle arrest, 
and prevents the outgrowth of resistant clones in long-term colony formation assays.    
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